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9ABSTRACT
Postoperative nausea and vomiting (PONV) are frequent complications having a medical
impact and a considerable economic impact. For surgical patients, PONV is a most distress-
ing adverse event, which they are reported to fear more often than postoperative pain.
This study evaluated different antiemetics, their combinations and dosing regimens in
various surgical settings among patients at high risk for PONV.
The antiemetic efficacy of 5-HT3 receptor antagonists ondansetron and tropisetron,
droperidol, dexamethasone and metoclopramide was investigated in altogether 5721 pa-
tients. Two 5-HT3 receptor antagonists, ondansetron 8 mg and tropisetron 5 mg, both
given intravenously and combined with intravenous droperidol 0.75 mg, were compared
when given for prophylaxis after gynaecological laparoscopy. Furthermore, the two 5-HT3
receptor antagonists, ondansetron 16 mg, tropisetron 5 mg were compared with
metoclopramide 10 mg given orally for prophylaxis with premedication before thyroid or
parathyroid surgery. The incidence of PONV in patients undergoing breast surgery after
sevoflurane anaesthesia with intravenous ondansetron 8 mg prophylaxis was compared
with propofol anaesthesia; sevoflurane anaesthesia without antiemetic prophylaxis served
as a control. Tropisetron 5 mg was compared with droperidol 1.25 mg, both given intrave-
nously at the beginning of laparoscopic cholecystectomy. Finally, ondansetron 4 mg, dex-
amethasone 4 mg and droperidol 1.25 mg, all given intravenously, were compared as
single, double and triple combinations for prophylaxis after various types of surgery.
Ondansetron 8 mg and tropisetron 5 mg, both combined with droperidol 0.75 mg,
resulted in the same incidence of PONV; 36% vs. 49%, respectively, P=0.28. The mean
time to the first dose of rescue medication was shorter after tropisetron prophylaxis com-
pared with ondansetron; 3 h 18 min vs. 6 h 25 min, P=0.007. Headache was significantly
more common after ondansetron prophylaxis than after tropisetron; 42% vs. 14%, P=0.004.
There was no difference among the groups in regard to other side effects. Oral ondansetron
16 mg, tropisetron 5 mg and metoclopramide 10 mg, resulted in the same incidence of
PONV, 68%, 58%, and 75%, respectively, during 0–24 h after surgery. During the early
phase of recovery (0–2 h) the incidence of PONV was lower after tropisetron prophylaxis
than after ondansetron and metoclopramide; 15%, 32%, and 39%, respectively, P=0.051
(tropisetron vs. ondansetron), P=0.004 (tropisetron vs. metoclopramide). The side effect
profile was similar after all three antiemetics. The patients were more satisfied with the
prophylaxis with tropisetron than metoclopramide; 10.0 vs. 8.0 (numeric rating scale, NRS),
P=0.001. The early (0–2 h) incidence of postoperative nausea was the same after propofol
anaesthesia and sevoflurane with ondansetron 8 mg prophylaxis, but was higher after
sevoflurane anaesthesia; 8%, 7%, and 32%, respectively, P=0.002 (propofol vs.
sevoflurane), P=0.001 (sevoflurane-ondansetron vs. sevoflurane). The incidence of vomit-
ing did not differ after the three anaesthesia regimens during this phase. Sevoflurane with
ondansetron resulted in a lower incidence of PONV compared with propofol or sevoflurane;
27%, 45%, and 60%, respectively, P=0.056 (sevoflurane-ondansetron vs. propofol),
P<0.001 (sevoflurane-ondansetron vs. sevoflurane) during the 24-hour study period. The
satisfaction of the patients was equal after all three anaesthesia types. Tropisetron 5 mg
and droperidol 1.25 mg prevented postoperative nausea as efficaciously; 55% vs. 62%,
respectively, ns., but tropisetron prevented vomiting more efficiently; 20% vs. 52%, re-
spectively, P=0.001. The patients were drowsier after droperidol prophylaxis, the median
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sedation score being 7 vs. 6, respectively (P=0.023). Otherwise the side effect profile of
the two prophylaxes did not differ. The prophylaxis with droperidol 1.25 mg, ondansetron
4 mg and dexamethasone 4 mg was associated with an early (0–2 h) reduction in the
incidence of PONV with adjusted odds ratios (OR) of 0.48, 0.65 and 0.73, respectively. The
double and triple combinations resulted in a decrease in the incidence of PONV with an
adjusted OR of 0.40 (ondansetron with dexamethasone), 0.31 (ondansetron with
droperidol), 0.46 (dexamethasone with droperidol) and 0.32 (ondansetron with dexam-
ethasone and droperidol). All the single prophylaxis regimens resulted in an equal reduc-
tion in the overall (0–24 h) incidence of PONV with an adjusted OR of 0.56 (ondansetron),
0.56 (dexamethasone) and 0.57 (droperidol). The double and triple combinations were
associated with a decrease with an adjusted OR of 0.34 (ondansetron with dexametha-
sone), 0.37 (ondansetron with droperidol), 0.36 (dexamethasone with droperidol) and
0.27 (ondansetron with dexamethasone and droperidol).
In conclusion, ondansetron and tropisetron are similar in the prevention of PONV. The
incidence of PONV is similar after propofol anaesthesia compared with sevoflurane anaes-
thesia with ondansetron prophylaxis, while sevoflurane anaesthesia without antiemetic
prophylaxis results in a significantly higher incidence of PONV. The anti-nausea effect of
tropisetron resembles that of droperidol. The late anti-vomiting effect of tropisetron is
stronger than that of droperidol. The antiemetic effect of ondansetron, droperidol and
dexamethasone given as single prophylaxis is similar cutting the incidence of PONV by
about 10–15%. All the double combinations of the drugs are equally effective, decreasing
further the incidence of PONV by 10%. The triple combination of the antiemetics reduces
the incidence of PONV additionally by 5%. Ondansetron, dexamethasone and droperidol,
given in double or triple combinations, act with an additive effect without synergism.
Altogether, either of the 5-HT3 receptor antagonists, ondansetron or tropisetron, can
be used for prophylaxis. When a patient with a moderate individual risk of (20–40%)
PONV is anaesthetized, either a volatile anaesthetic with antiemetic prophylaxis, or propofol,
can be chosen for maintenance. Any of the studied antiemetics, 5-HT3 receptor antago-
nist, dexamethasone and droperidol can be used for the prevention of PONV. When given
in combinations, all of the studied antiemetics act with additive effect without synergism.
For high risk patients (≥ 40%) propofol anaesthesia with a combination of at least two
antiemetics prophylaxis is recommended.
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INTRODUCTION
Despite the rapid progress in the field of modern anaesthesia, the incidence of postopera-
tive nausea and vomiting (PONV) still remains 25–30% (Lerman 1992). The increase of day
surgery in the 1990’s has been challenged by the high incidence of PONV. One of the
major limiting factors in the early discharge of day surgery patients is the presence of
PONV (Gold et al. 1989) implying that economic consequences are involved.
Managing PONV incurs costs for day surgery units through personnel costs associated
with the direct management of PONV, costs of drugs used to prevent and manage PONV,
costs of supplies used in caring for patients suffering from PONV, and costs associated
with the extra time spent by patients with PONV in the postanaesthesia care unit (PACU)
(Carroll et al. 1994). When all these costs were calculated, it was estimated that a delay in
discharge associated with PONV caused a $415 revenue loss in a U.S. outpatient surgical
center in 1994 (Carroll et al. 1994).
Several antiemetics have been investigated as prophylaxis of PONV. Traditional
antiemetics, droperidol and metoclopramide, have been studied in different surgical set-
tings (Henzi et al. 1999; Henzi et al. 2000). Newer agents, 5-hydroxytryptamine3 (5-HT3)
receptor antagonists were earlier shown to prevent effectively chemotherapy-induced nausea
and vomiting. During the past decade, 5-HT3 receptor antagonists have been investigated
extensively in the prevention of PONV (Tramèr et al. 1997). Dexamethasone, which simi-
larly was first used to prevent chemotherapy-induced emesis, has been lately investigated
for the prophylaxis of PONV (Henzi et al. 2000). The above agents in different combina-
tions have been studied too. A most impressive result was obtained when propofol anaes-
thesia was combined with droperidol, 5-HT3 receptor antagonist and dexamethasone pro-
phylaxis (Scuderi et al. 2000).
The cost-effective management of PONV as an objective, it has been debated whether
to prevent PONV or treat the established symptom. Using decision analysis, Watcha and
Smith (1994) found droperidol to be the most cost-effective antiemetic, followed by
ondansetron and metoclopramide. They concluded that prophylaxis was cost-effective, if
the incidence of PONV exceeded 30% (Watcha and Smith 1994). In another study per-
formed with a decision analysis model (Hill et al. 2000) droperidol 1.25 mg was more cost-
effective than droperidol 0.625 mg, ondansetron 4 mg or a strategy of treating only the
established symptom. The 1.25 mg dose of droperidol has also been shown to be more cost-
effective than a prophylactic 12.5 mg dose of dolasetron or placebo (Frighetto et al. 1999).
For patients PONV is a most distressing symptom. In addition to the costs, the un-
pleasantness of PONV has value for them. From the patients’ perspective, total avoidance
of PONV would be preferable. Indeed, the U.S. patients were willing to pay for a totally
effective antiemetic, and those with a history of PONV were willing to pay even extra (Gan
et al. 2001).
Antiemetic prophylaxis appears to be cost-effective when directed to patients who are
at high risk for PONV (Watcha and Smith 1994). Risk factors of PONV have been defined
during the past ten years. According to a simplified risk score to predict PONV (Apfel et al.
1999) the main risk factors for PONV are female gender, nonsmoking status, the history of
PONV or motion sickness, and the use of postoperative opioids.
The aim of the present study was to find a regimen to prevent PONV. The present
study compared the antiemetic efficacy of tropisetron, a 5-HT3 receptor antagonist, with
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droperidol, and that of tropisetron with ondansetron, another 5-HT3 receptor antagonist,
both in combination with droperidol. Also the antiemetic efficacy of the oral prophylaxis
with ondansetron, tropisetron and metoclopramide was compared. The incidence of PONV
after propofol anaesthesia was compared with sevoflurane anaesthesia with or without
ondansetron prophylaxis. Finally, the incidence of PONV after the single, double and triple
antiemetic prophylaxis with droperidol, ondansetron, and dexamethasone was compared.
All the comparisons were carried out among patients at high risk for PONV.
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REVIEW OF THE LITERATURE
INCIDENCE AND CLINICAL IMPLICATIONS OF POSTOPERATIVE NAUSEA AND
VOMITING
The overall incidence of PONV has been difficult to assess, as its aetiology is multifactorial
and there is seldom only one trigger stimulus. During the “ether age” the incidence of
PONV was reported to be as high as 75–80% (Blumfield 1899). At present, the overall
incidence of PONV after general anaesthesia has been estimated to range from 25% to
30% (Lerman 1992; Watcha and White 1992). The incidence of intractable nausea and
vomiting has been reported to be 0.18% (Gold et al. 1989).
Prolonged PONV may result in dehydration and electrolyte imbalance, and may expose
the patient to an increased risk of pulmonary aspiration of gastric contents, and may trigger
cardiorespiratory reflexes (Andrews 1992). Persistent vomiting can cause opening of the
sutures, especially in the head and neck area, and venous hypertension (Vance et al. 1973).
Intractable PONV can increase medical costs by increasing nursing care time, and delay-
ing discharge from the postanesthesia care unit (PACU) or leading to unanticipated hospital
admission (Gold et al. 1989; Carroll et al. 1995). Among ambulatory surgery patients, PONV
alone or combined with pain is the most common anaesthetic reason for delayed discharge
and unanticipated hospital admission (Gold et al. 1989; Hedayati and Fear 1999; Junger et
al. 2001; Wu et al. 2003). Nausea was reported to continue on average for 1.7 days and
vomiting for 0.7 days among outpatients suffering from the symptoms (Carroll et al. 1995).
From the patients’ point of view, PONV appears to be one of the most undesirable
postoperative complications (van Wijk and Smalhout 1990). When healthy subjects were
asked which adverse events they wanted to avoid, they were ready to accept moderate
pain, decreased alertness and extra payment to avoid PONV (Orkin 1992). Eberhart et al.
(2002) reconstructed the Orkin approach among patients scheduled for surgery under
general anaesthesia, and confirmed that patients were ready to accept a certain degree of
pain, drowsiness and additional costs to avoid PONV. In another study, in which patients
were asked which adverse events are important to prevent they rated vomiting the most
undesirable symptom, and even pain was rated less undesirable (Macario et al. 1999).
When the patients’ willingness to pay was assessed, they were ready to pay for a com-
pletely effective antiemetic (Gan et al. 2001). Those with a history of PONV were the most
willing to pay extra.
PHYSIOLOGY OF POSTOPERATIVE NAUSEA AND VOMITING
Vomiting is the forceful expulsion of gastrointestinal contents through the mouth. Retch-
ing is the rhythmic action of the respiratory muscles preceding vomiting. Both retching
and vomiting are objective patient experiences. Nausea is a subjective experience which
may or may not be associated with vomiting. (Andrews 1992)
The mechanism of the vomiting reflex was first described by Borison and Wang (1953)
to be a complex act involving the respiratory, gastrointestinal, and abdominal musculature
controlled by the vomiting centre. The vomiting centre is situated in the lateral reticular
formation close to the tractus solitarius in the brain stem (Borison 1989; Andrews et al.
1990). The vomiting centre can be triggered by stimuli from the periphery: the orophar-
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Table 1. Classes of different antiemetics, their sites of receptor antagonism, administration times for prophylaxis, doses for prophylaxis
and treatment, half-lives, contraindications and adverse effects. EPS=extrapyramidal symptoms, GI=gastrointestinal, NA=not assessed.
*Half-life of biological activity
Class Drug Site of Route Administration Dose for Dose for Max dose Half-life Contra- Adverse
receptor time for prophylaxis treatment per day indications effects
antagonism prophylaxis
Anticholinergics Atropine Acetylcholine IM, IV Premedication 0.01 mg/kg 2–3 h Urinary tract Dry mouth,
obstruction restlessness
Scopolamine IM, IV Premedication 0.2–0.65 mg Glaucoma Sedation, dry mouth,
TD 1.5 mg restlessness, central
cholinergic syndrome
Phenotiazines Chlorpromazine Dopamine2 IM, IV Premedication 25–50 mg 30 h Sedation, EPS,
PO 10–25 mg hypotension, restlessness
Promethazine IM, IV, Premedication 12.5–25 mg Sedation, EPS,
PO hypotension, restlessness
Perphenazine IM Premedication 2.5–5 mg 5 mg 10 h Pheochromo- Sedation, EPS
IV 1 mg cytoma hypotension, restlessness
PO 2–4 mg
Prochlorperazine IV Premedication 2.5–10 mg 40 mg Sedation, EPS,
IM, PO 5–10 mg hypotension, restlessness
5–10 mg
Butyrophenones Droperidol Dopamine2 IM, IV End of surgery 0.625–1.25 mg 0.625–1.25 mg 127 min Parkinson Sedation, EPS, QTc
disease prolongation, torsades de
pointes, neuroleptic
malignant syndrome
Haloperidol IM, IV End of surgery 0.5–4 mg 1 mg 12 h Parkinson Sedation, EPS, QTc
7 µg/kg disease prolongation
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Class Drug Site of Route Administration Dose for Dose for Max dose Half-life Contra- Adverse
receptor time for prophylaxis treatment per day indications effects
antagonism prophylaxis
Benzamides Metoclopramide Dopamine2 IM, IV End of surgery 10–20 mg 10–20 mg 1–2 h Pheochromo- Sedation, EPS
GI motility↑ cytoma
Antihistamines Cyclizine Histamine IM, IV, Premedication 25–50 mg 20 h Sedation, dry mouth,
PO restlessness
Hydroxyzine IM Induction of 25–100 mg 14 h Porphyria Sedation, dry mouth,
anaesthesia restlessness
PO Premedication 25–50 mg
Diphenhydramine IM, IV Premedication 10–50 mg 300 mg Sedation, dry mouth,
PO mg/kg restlessness
Serotonin Ondansetron 5-HT3; IV End of surgery 4–8 mg 1–4 mg 24 mg 3 Liver disease Headache, dizziness, liver
receptor central PO 8–16 mg enzyme elevation,
antagonists peripheral arrhythmias
Granisetron IV Induction of 1 mg 1 mg 3–6 h Liver disease Headache, dizziness
PO anaesthesia
Tropisetron IV Induction of 2–5 mg 2 mg 5 mg 8–42 h Liver disease Headache, dizziness
PO anaesthesia
Dolasetron IV During 12.5 mg 12.5 mg 4-8 h Liver disease Headache, dizziness, QT
PO anaesthesia 50 mg interval prolongation
Glucocorticoids Betamethasone Unknown IM Induction of 12 mg NA 5.5 h Adrenal suppression,
anaesthesia hyperglycaemia, wound
healing prolongation
Dexamethasone IV Induction of 2.5–5 mg NA 3.5 h Adrenal suppression,
anaesthesia 36–72h* hyperglycaemia, wound
healing prolongation
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ynx, the gastrointestinal tract, the mediastinum, renal pelvis, peritoneum and genitalia,
and centrally from the CNS: cerebral cortex, labyrinthine, the visual centre, the vestibular
portion of the eighth cranial nerve, and the chemoreceptor trigger zone (CTZ) located in
the area postrema at the base of the fourth ventricle (Borison and McCarthy 1983; Andrews
et al. 1990). As the area postrema has no effective blood-brain barrier, CTZ can be directly
stimulated by chemicals in the cerebrospinal fluid (CSF) and blood (Andrews 1992).
The CTZ has high concentrations of encephalin, dopamine, and opioid receptors. The
area postrema is rich in opioid, dopamine (D) and serotonin (5-hydroxytryptamine (5-HT))
receptors. The nucleus of the solitary tract contains high concentrations of encephalin,
histamine, muscarinic (M), and cholinergic receptors (Kovac 2000). Recently, substance P
and neurokinin-1 (NK1) receptors were found to be involved in the regulation of emesis
(Maubach and Jones 1997). At present it is generally accepted that the key to control
PONV is the blocking of all the recognized receptors involved in emesis (Heffernan and
Rowbotham 2000). (Figure 1, Table 1 on the previous page).
Figure 1. Agonists and antagonists associated with nausea and vomiting.
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RISK FACTORS FOR POSTOPERATIVE NAUSEA AND VOMITING
Predictive scores for postoperative nausea and vomiting
In order to direct the antiemetic prophylaxis to the patients at high risk, several attempts
have been made to identify the risk factors for PONV. During the 1990s, several indepen-
dent models using logistic regression were created for this purpose (Palazzo and Evans
1993; Koivuranta et al. 1997; Apfel et al. 1998; Sinclair et al. 1999) (Table 2).
Palazzo and Evans (1993) studied 147 patients undergoing orthopaedic surgery (Table
2). The total incidence of vomiting was 27% in their study. They concluded that the history
of PONV, female gender, the history of motion sickness and interaction between gender,
history of PONV and postoperative opioids are fixed risk factors. The relative effects of the
factors are summarized in an equation as follows:
Logit postoperative sickness = –5.03 + 2.24 (if postoperative opioids were used) + 3.97 (if
previous PONV) + 2.4 (if female) + 0.78 (if history of motion sickness) – 3.2 (if female with
previous PONV).
Toner et al. (1996) further tested the above model in another hospital in 400 patients
undergoing various types of surgery. According to their study the accuracy of the equation
in predicting the risk for PONV in a single patient is limited. However, the model was
effective in predicting the risk of PONV in groups of patients with various combinations of
risk factors.
Koivuranta et al. (1997) surveyed 1107 inpatients undergoing various types of surgery
(Table 2). The incidence of nausea was 52% and the incidence of vomiting 25% during
the entire 24 h study period. According to the survey female gender, the history of PONV,
long duration of surgery, the history of motion sickness, and nonsmoking are patient-
related risk factors. The authors constructed the following risk score for PONV:
Score = 0.93 (if female) + 0.82 (if previous PONV) + 0.75 (if duration of surgery over 60
min) + 0.61 (if nonsmoker) + 0.59 (if history of motion sickness).
The risk score of Apfel et al. (1998) was based on the data of 1137 patients undergoing
ear, nose and throat surgery (Table 2).  Only postoperative vomiting (POV) was studied, not
postoperative nausea.  The data of 1137 patients was split randomly into an evaluation set
and a validation set, and the incidence of POV was 21% and 22% in the sets, respectively.
According to the study age, gender, the history of motion sickness and/or POV, nonsmok-
ing status and the duration of anaesthesia are independent risk factors. The risk of POV
can be estimated from the equation:
Risk (probability of POV) = 1 / (1 + e-z), where z = 1.28 (female gender) – 0.029 (age) – 0.74
(smoking) + 0.63 (history of PONV or motion sickness) + 0.26 (duration) – 0.92.
The discrimination power of the score was then tested among 1091 patients undergoing
various types of ophthalmologic and surgical operations under general anaesthesia with
volatile anaesthetics, and found to be accurate (Apfel et al. 1998).
Sinclair et al. (1999) studied 17,638 outpatients; they found the incidence of PONV to
be 4.6% in the PACU and 9.1% within 24 h of the surgery (Table 2). The patient popula-
tion was divided into a model development set and a model validation set. The logistic
regression model for assessing the risk of PONV age, gender, smoking status, history of
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Table 2. Patient, anaesthesia and surgery related risk factors for postoperative nausea and/or vomiting in risk scores for predicting PONV.
++ = strong correlation, + = some correlation, – = no correlation. *Oulu **Würzburg
Authors  Study characteristics Factors in the score
Number of Types of Primary Total Female Non- History History BMI Age History of Use of Long Type of Type of
patients surgery endpoint incidence (%) gender smoking of PONV of motion migraine post- duration anaesthesia surgery
of nausea sickness operative of
and/or opioids anaesthesia
vomiting
Palazzo
& Evans 147 Orthopaedic Vomiting 27 ++ NA ++ + – – NA ++ – NA NA
1993
Koivuranta 1107 Various Nausea 52 ++ ++ ++ ++ – – – ++ ++ – +
et al. 1997 Vomiting 25 ++ – ++ – – – – – ++ – +
Apfel 1137 Ear, nose Vomiting 22 ++ ++ ++ ++ – ++ NA – ++ NA NA
et al. 1998 and throat
Sinclair 17638 Various Nausea and 9 ++ ++ ++ ++ – ++ NA + ++ ++ ++
et al.1999 vomiting
Apfel et al. 520 *+ Various Nausea and 56* ++ ++ ++ ++ – – NA ++ – NA –
1999 2202** vomiting 31**
Stadler 671 Various Nausea 19 ++ ++ – – – – + + – ++ ++
et al. 2003 Vomiting 10 ++ ++ – – – – – + – ++ –
PONV= postoperative nausea and vomiting, BMI = body mass index, NA = not applicable.
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PONV, type and duration of anaesthesia, and type of surgery were included as indepen-
dent factors (Sinclair et al. 1999).
The data of Koivuranta and Apfel scores were cross-validated afterwards by the two
centres (Apfel et al. 1999), and a simplified risk score was developed without losing dis-
criminating power (Table 2). The simplified risk score included female gender, history of
motion sickness or PONV, nonsmoking status, and the use of postoperative opioids. If
none, one, two, three, or four of the risk factors were present, the incidence of PONV was
10%, 21%, 39%, 61% and 79%, respectively (Figure 2).
Figure 2. Flow chart for assessing the individual risk for postoperative nausea and
vomiting according to Apfel et al. (1999) and suggested anaesthetic and antiemetic
regimen.
When the first three scores (Palazzo and Evans 1993; Koivuranta et al. 1997; Apfel et al.
1998) were evaluated, they all predicted PONV and POV with moderate accuracy, but the
score presented by Koivuranta was recommended for clinical use as it is easy to calculate
(Eberhart et al. 2000). Compared with the scores presented by Palazzo & Evans and Sinclair,
the score published by Koivuranta and the simplified Apfel score predicts PONV with better
discrimination power (Apfel et al. 2002). In another comparison with the Sinclair score (Pierre
et al. 2002), the simplified Apfel score presented with favourable discriminating and calibra-
tion properties for predicting the risk of PONV. However, when the simplified Apfel score and
the scores published by Palazzo & Evans, Koivuranta and Sinclair were evaluated, the agree-
ment between them was found to be poor, and the authors claimed that this limited the
usefulness of the scores (Thomas et al. 2002).
Recently, an epidemiologic study of  671 patients identified risk factors for postopera-
tive nausea and vomiting as separate symptoms (Stadler et al. 2003) (Table 2). According
to this survey, female gender, nonsmoking status and general anaesthesia are risk factors
for both symptoms, while history of migraine and the type of surgery, urological surgery
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excluded, increase nausea only. In the study by Stadler and co-workers, the history of
PONV or motion sickness did not increase the risk of PONV.
Investigated separately, smoking was shown to reduce the risk of PONV (Chimbira and
Sweeney 2000). The effect of smoking in reducing the risk of PONV has been suggested to
result from the dopaminergic stimulus (Apfel et al. 1998) or the increased metabolism of
the anaesthetic agents via induction of the hepatic P450 enzyme (Chimbira and Sweeney
2000; Sweeney 2002). On the other hand, when the impact of obesity on the risk for
PONV was studied separately, it was not found to be a risk factor (Kranke et al. 2001).
Perioperative gastric emptying appeared not to be a predictor of early PONV in patients
undergoing laparoscopic cholecystectomy (Wattwil et al. 2002).
Anaesthesia-related factors
Premedication
Premedication with opioids stimulates CNS opioid receptors and, therefore, may increase
the incidence of PONV (Dundee et al. 1965). The incidence of PONV was shown to in-
crease after intramuscular, intravenous, nasal, oral, and transmucosal administration of
opioids (Henderson et al. 1988; Nelson et al. 1989; Pandit and Kothary 1989).
The combination of anticholinergics with opioids was shown to decrease the inci-
dence of PONV (Dundee et al. 1965). As scopolamine has a considerable sedative effect, it
has been used for premedication. Transdermal scopolamine in children before strabismus
surgery decreased the incidence of POV (Horimoto et al. 1991). Compared with atropine,
glycopyrrolate appears to possess no antiemetic effect (Salmenperä et al. 1992), probably
because it does not cross the blood-brain barrier.
Used as premedication, benzodiazepines have been suggested to reduce the incidence
of PONV by decreasing the plasma levels of catecholamines (Jenkins and Lahay 1971), but
the finding has not been confirmed.
Clonidine, an alpha2 adrenergic agonist is an interesting option for premedication
because of its sedative property, and given as premedication before strabismus surgery it
decreases the incidence of PONV in children (Mikawa et al. 1995).
Altogether, appropriately chosen premedication may reduce the incidence of PONV by
relieving the anxiety and distress of patients.
Intravenous anaesthetics
Propofol is an IV anaesthetic used for the induction and maintenance of general anaesthe-
sia, sedation for short and long operations, and in intensive care, and as an antiemetic at
subhypnotic doses (Rose and Watcha 1999). At a subhypnotic dose of 10 mg it is claimed
to have a direct antiemetic effect when administered to treat established PONV in patients
after general anaesthesia (Borgeat et al. 1992). Administered 20 hours after thyroidec-
tomy at an infusion rate of 0.1 mg/kg/h propofol decreased the incidence of PONV in
comparison with placebo (10% vs. 65%, respectively) (Ewalenko et al. 1996). A bolus
dose of 10 mg followed by an infusion of 10 µg/kg was determined to reduce the inci-
dence of PONV by 50% in patients after general anaesthesia in the PACU (Gan et al.
1997). The mechanism of the antiemetic effect of propofol is unclear. Propofol does not
antagonize D2 receptors, but may depress directly the CTZ, vagal nuclei and other centres
involved with nausea and vomiting (Appadu et al. 1994). When nausea and vomiting were
induced by the 5-HT releaser ipecacuanha in healthy volunteers, propofol reduced the
23
number and intensity of emetic events compared with placebo (Hammas et al. 1998). In
rats propofol was shown to reduce the level of serotonin in the area postrema and the
cerebrospinal fluid by γ-aminobutyric acidA (GABAA)- mediated inhibition of the release of
5-HT, and possibly to reduce directly the neuronal activity via GABAA in the area postrema
(Cechetto et al. 2001).
When compared to thiopentone as an induction agent, propofol reduced the inci-
dence of PONV (odds ratio (OR) 0.82, P=0.03) in a study on 4173 patients (Myles et al.
1996). However, according to a meta-analysis, when used for induction of anaesthesia,
the number needed to treat (NNT) of propofol was 9 and when used for maintenance, the
NNT was 6 (Tramèr et al. 1997). For patients at high risk for PONV (20–60%), propofol
appeared to have the best efficacy on early PONV with a NNT of 4.7. Consequently, high-
risk patients benefited from the propofol maintenance. Intravenous induction of anaes-
thesia with propofol has no effect on the incidence of PONV (Tramèr et al. 1997).
Because barbiturates are used only for inducing anaesthesia, and not for its mainte-
nance, their emetogenic property is difficult to assess (Rose and Watcha 1999).
Methohexithone as a sole anaesthetic resulted in a higher incidence of PONV compared
with propofol after microlaryngeal surgery (Best and Traugott 1991). The use of the steroid
hypnotic eltanolone resulted in a similar incidence of PONV compared with propofol and
thiopentone in anaesthesia for termination of pregnancy (Kallela et al. 1994; Eriksson et
al. 1995). The incidence of PONV was similar after the induction of anaesthesia with
etomidate and propofol in the early period of recovery, but the incidence was lower after
propofol induction in the late postoperative period (St Pierre et al. 2000). Ketamine, a
dissociative anaesthetic which has been used as an adjuvant in anaesthesia for its analge-
sic properties, is associated with a dose-dependent increase in the incidence of PONV
(Badrinath et al. 2000).
In conclusion, patients at high risk for PONV benefit from propofol maintenance, while
propofol used only for induction of anaesthesia does not reduce the incidence of PONV.
Anaesthetic gases
The inhaled anaesthetics used earlier, i.e. ether and cyclopropane, appeared to be more
emetogenic than the halogenated anaesthetics, i.e. halothane, enflurane, isoflurane,
sevoflurane and desflurane, of today (Bellville et al. 1960; Clarke 1984; Palazzo and Strunin
1984). The emetic property of the old inhalational agents may result from the increase in
catecholamines associated with their use (Jenkins and Lahay 1971). However, according to
a recent study, inhaled anaesthetics appear to be the main cause of PONV in the early
phase of postoperative recovery, but they seem not to be associated with the occurrence
of the delayed PONV (Apfel et al. 2002). In the study of Apfel et al. the incidence of PONV
did not differ after isoflurane, enflurane or sevoflurane anaesthesia. The incidence of emetic
events was also similar after sevoflurane and desflurane used in outpatient anaesthesia
(33% vs. 38%, respectively) (Nathanson et al. 1995) and videoarthroscopy of the knee
(8% vs.16%, respectively) (Naidu-Sjösvärd et al. 1998). However, sevoflurane resulted in a
lower incidence of PONV compared with isoflurane (9% vs. 24%) in a multicentre trial
conducted among adult ambulatory patients (Philip et al. 1996). Isoflurane maintenance,
on the contrary, resulted in a lower incidence of PONV compared with desflurane and
sevoflurane (22% vs. 67% vs. 36%, respectively) after breast surgery (Karlsen et al. 2000).
The incidence of emetic events has been compared in several trials after different
inhaled anaesthetics and after propofol. In general, the incidence of PONV is lower after
propofol maintenance than after maintenance with inhaled anaesthetics. A meta-analysis
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showed a lower incidence of PONV after propofol maintenance compared with any inha-
lational agent (Sneyd et al. 1998). In inpatients undergoing surgery under general anaes-
thesia, Rowbotham et al. (1998) showed that total IV anaesthesia with propofol resulted
in a decreased incidence of PONV compared with isoflurane, both in combination with
remifentanil-infusion (complete response 68% vs. 50%, respectively). In a large trial
(n=2010) total IV anaesthesia with propofol resulted in a reduced incidence of PONV com-
pared with isoflurane during the first 24 h after surgery (31% vs. 40% among inpatients,
17% vs. 29% among outpatients) (Visser et al. 2001). During hours 24 to 72 the inci-
dence of emetic events did not differ between the two anaesthesia groups. Sevoflurane
induction followed by sevoflurane maintenance resulted in a higher incidence of POV
compared with propofol induction followed by propofol maintenance in patients under-
going outpatient surgery; 33% vs. 10%, respectively (Fredman et al. 1995) and 32% vs.
18%, respectively (Ræder et al. 1997). However, the occurrence of PONV was similar after
sevoflurane vs. propofol and sevoflurane vs. isoflurane anaesthesia (48% vs. 40% and
51% vs. 50%, respectively) among patients scheduled for surgery under general anaes-
thesia (Ebert et al. 1998). Desflurane resulted in a higher incidence of PONV compared
with desflurane in combination with ondansetron or propofol maintenance (51% vs. 24%
vs. 24%, respectively) among outpatients undergoing gynaecological laparoscopy (Eriksson
and Korttila 1996). Desflurane and propofol maintenance, both in combination with
ondansetron 0.05 mg/kg and droperidol 20 µg/kg, led to a similar incidence of PONV
(33% vs. 43%, respectively) after outpatient laparoscopic cholecystectomy (Ræder
et al. 1998). In conclusion, propofol induction followed by propofol maintenance is war-
ranted for high-risk patients. The emetic properties of inhalational agents do not differ
from each other.
For decades, nitrous oxide (N2O) has been considered an emetic agent and generally
believed to increase the incidence of PONV. N2O can induce PONV by penetrating into
closed spaces such as bowel (Eger and Saidman 1965; Giuffre and Gross 1986), by activat-
ing the medullary dopaminergic system (Murakawa et al. 1994) and increasing cerebrospi-
nal opioid peptides (Finck et al. 1995). In the mid-1990s, three meta-analyses or reviews
evaluated the evidence of N2O in regard to PONV (Divatia et al. 1996; Hartung 1996;
Tramèr et al. 1996). According to Hartung, in 24 out of 27 studies the incidence of emetic
events was higher when N2O was omitted, but the analysis does not meet the criteria of a
systematic review followed by a meta-analysis. Divatia et al. concluded that omission of
N2O reduced the odds of PONV by 37%. Tramèr et al. showed that omitting N2O de-
creased the incidence of vomiting when the control incidence was high (NNT 5), and
decreased the incidence less when the control incidence was low (NNT 13). Nevertheless,
the investigators concluded that omitting N2O had no effect on nausea or complete con-
trol of emesis. Having several benefits, such as analgesic and hypnotic effects, predictabil-
ity, fast onset and offset, and low cost (Ræder 1994), N2O has retained its position in
common anaesthesia practice. An anaesthesia regimen without nitrous oxide may be jus-
tified for patients at high risk for PONV (Tramèr et al. 1996).
Altogether, volatile anaesthetics appear to be the leading cause of PONV in the early
phase of recovery. The pro-emetic activity of different volatile anaesthetics is very similar.
Omitting N2O reduces the incidence of vomiting but does not influence the incidence of
nausea.
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Intraoperative opioids
The association between pain, administered opioids and PONV is complex. In the postop-
erative period both pain (Andersen and Krohg 1976; Chia et al. 2002) and opioids have
been reported to increase the incidence of PONV. In the logistic regression models of the
risk factors for PONV (Palazzo and Evans 1993; Koivuranta et al. 1997; Apfel et al. 1998;
Apfel et al. 1999) the use of postoperative opioids was included, while the use of intraop-
erative opioids was not. In the survey by Stadler et al. (2003) patients with and without
PONV received equal amounts of sufentanil during the anaesthesia. When the beta-adren-
ergic blocking agent esmolol was compared with the ultrashort-acting opioid remifentanil
as anaesthesia adjuvant, the incidence of PONV was significantly higher after remifentanil
infusion, but the patient satisfaction was equal after both treatments (Coloma et al. 2001).
Remifentanil was compared with alfentanil, both in combination with propofol, and the
incidence of PONV was equal in both groups (Dershwitz et al. 2002; Ozkose et al. 2002).
In a comparison of fentanyl-propofol with ketamine-propofol in outpatient tubal ligations,
there was no difference in PONV between the groups (Vallejo et al. 2002).  According to
the data of today, therefore, the association of intraoperative opioids with PONV is not
clear.
Reversal of muscle relaxation
The use of muscle relaxants has not been associated with a higher incidence of PONV. The
antagonism of muscle relaxation with neostigmine has been widely investigated in regard
to PONV. The emetic effect is claimed to be prevented by using atropine concurrently with
neostigmine (Salmenperä et al. 1992). The results of the trials concerning neostigmine in
regard to PONV are contradictory. However, a systematic review by Tramèr and Fuchs-
Buder (1999) showed a slight decrease in the incidence of PONV when the antagonism
with neostigmine was omitted, as well as some evidence of dose-responsiveness for neo-
stigmine. A 2.5 mg dose of neostigmine appeared to be emetogenic. A similar finding
concerning the dose-responsiveness of neostigmine was published by Løvstadt et al. (2001).
Postoperative pain and analgesics
Postoperative pain, especially when its origin is visceral, was shown to be a considerable
cause of PONV (Andersen and Krohg 1976; Chia et al. 2002). On the other hand, PONV is
a well-known side effect of opioids, and the emetic centre has plenty of opioid receptors.
In a simplified risk score of Apfel et al. (1999), the use of postoperative opioids has been
identified to be an independent risk factor for PONV. In a recent survey, the growing dose
of morphine administered after surgery increased the incidence of PONV, whereas postop-
erative pain did not influence PONV (Stadler et al. 2003). At present, a multimodal ap-
proach to treat postoperative pain is generally recommended to prevent postoperative
emetic events. The multimodal approach consists of the use of regional anaesthesia when-
ever possible, and regular dosing of nonsteroidal analgesic inflammatory drugs (NSAID)
and paracetamol (Jin and Chung 2001). There is evidence that NSAIDs and paracetamol,
given concurrently with premedication, decrease the need for opioids in the postoperative
period (Montgomery et al. 1996). A multimodal analgesia with lidocaine gel on the steril-
ization clips and ketoprofen IV lowered the pain and nausea scores, and lessened the need
for opioids and antiemetics in comparison to either of the analgesic regimens alone after
outpatient tubal ligation (Eriksson et al. 1996).
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There is little evidence in the literature that the emetic properties of opioids differ.
However, postoperative pethidine was shown to lead to a higher incidence of PONV when
compared with morphine (Ezri et al. 2002). It is possible that the incidence of PONV and
the other side effects of opioids decrease, if they are administered orally instead of IV or
IM. The oral administration of the slow-release opioid oxycodone was shown to reduce
the total dose of opioid needed, and consequently the incidence of PONV compared with
immediate-release oxycodone within the first three postoperative days after outpatient
anterior cruciate ligament surgery (Reuben et al. 1999). Furthermore, slow-release
oxycodone given as premedication before ambulatory laparoscopic tubal ligation was re-
ported to result in a lower incidence of PONV when compared with the traditional IV
administration of fentanyl postoperatively (Reuben et al. 2002).
Operation-related factors
There is evidence that surgery in the head, neck and ear, nose and throat, plastic,
gynaecological and abdominal surgery are associated with a high incidence of PONV
(Honkavaara et al. 1994; Sonner et al. 1997). It appears that the patient-related risk fac-
tors are the most important ones to be considered (Apfel et al. 1999). However, in a recent
epidemiological study the type of surgery, urological surgery excluded, appeared to influ-
ence the incidence of nausea but not of vomiting (Stadler et al. 2003). In the study of
Stadler et al. (2003) the highest incidence of PONV occurred among patients undergoing
gynaecological (32%), abdominal (26%), maxillofacial (27%), plastic (25%), neurosurgi-
cal (24%) and urological (19%) surgery. In certain cases, e.g. a patient with wired jaws,
and after plastic or thyroid surgery, the consequences of emesis may be hazardous and/or
destroy the outcome of the surgery. Situations like this justify the employment of all avail-
able preventive measures.
PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
Anticholinergics
The cerebral cortex and pons are rich with different cholinergic and muscarinic receptors
(McCarthy and Peroutka 1988). Muscarinic subtype-3 and subtype-5 receptor antagonists
act as antiemetics (Kovac 2000). (Figure 1) Atropine and scopolamine cross the blood-
brain barrier and help to prevent motion sickness and PONV. There is evidence that the use
of glycopyrrolate, instead of atropine, results in a higher incidence of PONV (Salmenperä
et al. 1992). Glycopyrrolate 10 µg/kg and neostigmine resulted in a higher incidence of
POV compared with atropine 15 µg/kg (81% vs. 56%, respectively) also among children
undergoing tonsillectomy with or without adenoidectomy (Chhibber et al. 1999). On the
other hand, compared with placebo, glycopyrrolate given before spinal anaesthesia for
caesarean section, resulted in a lower incidence of PONV (Ure et al. 1999). By adding
anticholinergic drugs like atropine and scopolamine to an opioid for premedication, the
incidence of PONV can be decreased (Dundee et al. 1965). In a recent meta-analysis,
transdermal scopolamine was shown to prevent PONV effectively (Kranke et al. 2002).
However, the incidence of side effects was inexcusably high. The most often complained
of side effects are visual disturbances, sedation, dry mouth, dizziness and memory dys-
function.
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Dopamine receptor antagonists
Phenothiazines (e.g. promethazine, prochlorperazine), butyrophenones (droperidol, halo-
peridol), and benzamides (metoclopramide) are strong dopamine-2 (D2) receptor antago-
nists. (Figure 1)
Phenothiazines
Phenothiazines, i.e. promethazine, chlorpromazine, prochlorperazine, perphenazine,
thiethylperazine, have been widely used for the prevention and treatment of postopera-
tive emesis. The compounds consist of a tricyclic nucleus with an aliphatic (promethazine,
chlorpromazine) or heterocyclic (prochlorperazine, perfenazine, thiethylperazine) ring at-
tached to it. The antiemetic activity appears to be higher, and the sedative effect lower, of
those phenothiazines with a heterocyclic ring than of those with an aliphatic ring (Dundee
et al. 1965). The phenothiazines block directly the D2 receptors in the CTZ, having also
some antihistaminergic and anticholinergic action. They act as sedatives and counter the
effect of e.g. opioids in the CTZ (Howat 1960; Dundee et al. 1965; Wood 1979). The side
effect profile of phenothiazines is much like that of the other dopamine receptor antago-
nists. The incidence of extrapyramidal symptoms is higher with the heterocyclic phenothi-
azines than the aliphatic ones (Howat 1960; Dundee et al. 1965; Dundee et al. 1975). The
neuroleptic malignant syndrome is a rare side effect, which has been reported with all the
dopamine receptor antagonists (Kovac 2000).
The tricyclic nucleus of heterocyclic phenothiazines has a piperazine ring at the tenth
position of the nucleus. Prochlorperazine and perfenazine are the most widely used het-
erocyclic phenothiazines, and they are claimed to exert antiemetic activity against emesis
caused by opioids (Dundee et al. 1975; Kovac 2000).
Butyrophenones
Butyrophenones, i.e. haloperidol and droperidol, are strong D2 receptor antagonists acting
at the CTZ and area postrema (Loeser et al. 1979). Both are effective antiemetics for the
prophylaxis and treatment of PONV (Kovac 2000). Droperidol has been studied widely in
different anaesthetic settings, but among anaesthesiologists the experience of haloperidol
may be limited to its use in chronic pain. The mean elimination half life of droperidol is 127
min (Lehmann et al. 1988). At large doses, 2.5 mg to 5 mg, the risk of potential side
effects of droperidol, such as drowsiness, restlessness, abnormal movements, dizziness,
vertigo, anxiety and extrapyramidal symptoms increases (Henzi et al. 2000). In this system-
atic review, droperidol proved to be antiemetic, but this effect is short-lived. Its effect on
nausea is more pronounced than its effect on vomiting. According to the systematic re-
view (Henzi et al. 2000) the anti-nausea effect of droperidol is not dose-dependent, while
its anti-vomiting effect appears to be dose-dependent. There was dose-responsiveness for
adverse events associated with droperidol (Henzi et al. 2000). Droperidol appears to pos-
sess antiemetic activity in prophylaxis, even at small doses of 0.625 mg (Kreisler et al.
2000). However, in a placebo-controlled multicentre trial on 2061 patients, a 1.25 mg
dose of droperidol compared favourably with a dose of 0.625 mg, as well as with 4 mg of
ondansetron, when one weighs the costs against the benefits gained from having a addi-
tional PONV-free, side-effect-free patient as a result of successful prophylaxis (Hill et al.
2000). At a dose of 20 µg/kg droperidol was shown to prevent postoperative emesis effec-
tively among female patients but not among male patients, whose incidence of PONV
is low anyway (Hechler et al. 2001). For nausea and vomiting caused by opioid–patient–
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controlled–analgesia (PCA), droperidol seems to be the only effective antiemetic at a dose
0.017–0.17 mg/mg of morphine (Tramèr and Walder 1999). When droperidol is used for
this purpose, there is no evidence of dose-responsiveness for its efficacy, but the risk of
adverse events is dose-dependent. Epidurally administered droperidol appeared to prevent
nausea, vomiting and pruritus, while IV administered droperidol prevented only nausea
and vomiting (Nakata et al. 2002). When 0.625 mg of droperidol was given for antiemetic
prophylaxis before gynaecological dilatation and curettage in a placebo-controlled trial,
body sway was significantly greater in the droperidol group at the time of achieving a
post-anaesthesia discharge score of 9 (approximately 36 min after surgery), but no longer
at the time of discharge home (approximately 92–102 min after surgery) (Song et al. 2002).
In this trial the body sway velocity was assessed while the patient was standing first on a
firm surface, then on a foam surface with eyes open and closed. The data is inconsistent
for optimal timing of the prophylactic dose (Henzi et al. 2000). Based on the pharmacoki-
netics, the prophylactic dose of droperidol should probably be given at the end of anaes-
thesia (Henzi et al. 2000).
After over 30 years of clinical use of droperidol in anaesthetic practice, a “black box”
warning was placed in the labels by the United States Food and Drug Administration (FDA)
in December 2001. In Europe, droperidol has been withdrawn in the United Kingdom and
Spain. The FDA warning was based on the dose-dependency in cases of prolonging the
corrected QT interval (QTc) and torsades de pointes associated with the use of droperidol
(Gan et al. 2002). The warning consists of a recommendation for a pre-treatment screen-
ing by 12-lead electrocardiogram (ECG) and extended ECG monitoring for up to three
hours (White 2002). The FDA decision has met strong criticism for being unjustified, as the
arrhythmias and electrophysiological changes associated with droperidol appear to be ex-
tremely rare (Ben-David et al. 2002; Gan et al. 2002). From November 1997 until the end
of January 2002 altogether 273 individual safety reports concerning droperidol were pro-
cessed; 120 of them dealt with cardiac or respiratory events (Dershwitz 2002). Of these
120 cases 19 involved doses smaller than 10 mg. Moreover, most of the reports concern-
ing anaesthetic doses contained confounding factors (Dershwitz 2002). In the anaesthetic
setting, droperidol is typically given while the patients are being continuously monitored
by ECG (White 2002). Furthermore, prolongation of the QT interval has been reported
when 5-HT3 receptor antagonist dolasetron has been given, and arrhythmia has occurred
when another drug of the same class, ondansetron, has been administered concurrently
with metoclopramide (Baguley et al. 1997; Kantor 2002). A black box warning has never-
theless not been added to the labels of these drugs. For the time being, the FDA is per-
forming a pharmacokinetic and pharmacodynamic study to define the effects of 0.625
mg, 2.5 mg and 5 mg doses of droperidol on the QTc interval (McCormick 2002). The FDA
will not make liberations concerning the recommendations on the use of droperidol, be-
fore the results of the study are available. Nevertheless, the study carried out by the FDA
has been claimed to have a surrogate endpoint (Scuderi 2003). It was proposed that an
acceptable risk be established for antiemetic use, based on the risk associated with un-
treated postoperative vomiting (Scuderi 2003). Also the risk of adverse events associated
with other commonly used antiemetics should be investigated (Scuderi 2003).
Benzamides
Metoclopramide and domperidone are benzamides which are strong D2 antagonists.
Metoclopramide is the most effective and most widely used antiemetic in the class (Rose
and Watcha 1999) acting both centrally in CTZ and in the area postrema, and in the
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periphery, i.e. gastrointestinal tract (Harrington et al. 1983). It does not have
antihistaminergic properties (Kovac 2000). Metoclopramide increases lower oesophageal
sphincter tone and promotes gastric motility from the distal oesophagus to the ileocaecal
valve (Rose and Watcha 1999).  The side effect profile of metoclopramide is much like that
of the other dopamine receptor antagonists: extrapyramidal symptoms, sedation, dizzi-
ness, drowsiness, but the side effects appear to be milder (Henzi et al. 1999). Having a
relatively short duration of action, metoclopramide should be given at the end of surgery
(Kovac 2000). In a meta-analysis a 10 mg dose of metoclopramide IV was the best docu-
mented regimen (Henzi et al. 1999), but the dose appeared to be ineffective as an anti-
emetic prophylaxis, and did not show an increased risk of adverse events either. However,
the authors state that the doses used in anaesthetic practice are too low. In chemotherapy-
induced nausea and vomiting, much higher doses of metoclopramide, 2 mg/kg, resulted
in a lower incidence of emesis compared with placebo, with only minor side effects
(Gralla et al. 1981).
Antihistamines
Antihistamines (dimenhydrinate, diphenhydramine, cyclizine, hydroxyzine) block acetyl-
choline in the vestibular apparatus and histamine H1 receptors in the nucleus of the soli-
tary tract. (Figure 1) They act mainly in the vomiting centre and vestibular pathways, acting
only slightly in the CTZ. Antihistamines are effective for treating vertigo and motion sick-
ness (Dundee et al. 1975; McKenzie et al. 1981). For the prevention of chemotherapy-
induced nausea and vomiting they have been usually combined with other antiemetics, as
they counteract the extrapyramidal effects of dopamine receptor antagonists (Rose and
Watcha 1999). Their use may be justified when preventing PONV resulting from vestibular
stimulation such as in middle ear surgery and in patients with motion sickness (Rose and
Watcha 1999). Their main side effects are sedation and drowsiness, dry mouth, vision
disturbances, urinary retention and prolonged recovery (Kovac 2000). Their sedative effect
prevents their use in the postoperative period, at least in outpatients.
In a recent meta-analysis, dimenhydrinate was shown to prevent PONV in the early
phase of recovery with NNT 8 and in the whole investigated period with NNT 5 (Kranke et
al. 2002), but the side effects were poorly documented.
Serotonin receptor antagonists
The 5-HT3 receptor is highly specific and selective for nausea and vomiting. The key to
discovering the serotonin receptor antagonists was the finding that compounds resem-
bling metoclopramide structurally lacked dopamine receptor affinity but had antiemetic
activity. (Figure 1) These compounds appeared to be specific and selective 5-HT3 receptor
antagonists. After they were shown to be effective in nausea and vomiting resulting from
chemotherapy and radiotherapy, they were introduced for anaesthetic practice. The first
agent of the class to be utilized was ondansetron in 1991, and later in the 1990s granisetron,
tropisetron and dolasetron became available (Rose and Watcha 1999). The advantage of
the drugs of this class is their favourable side effect profile with no adverse events of
dopamine, muscarinic and histaminergic receptor antagonists (Rose and Watcha 1999).
Ondansetron
Since ondansetron was launched, it has been investigated widely in different surgical set-
tings, and by now it is the best documented 5-HT3 receptor antagonist regarding efficacy
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on PONV. The bioavailability of the drug is approximately 60% when given orally to healthy
volunteers. The mean elimination half-life of ondansetron is 3 hours (Markham and Sorkin
1993). In several meta-analyses, the antiemetic efficacy of ondansetron has been proven
to be superior to placebo and metoclopramide and equal to that of droperidol and dexam-
ethasone (Tramèr et al. 1997; Figueredo and Canosa 1998; Domino et al. 1999). For the
prevention of PONV, an 8 mg dose of ondansetron IV was not more effective than a 4 mg
dose (Tramèr et al. 1997; Figueredo and Canosa 1998). In one of the systematic reviews,
the anti-vomiting effect of ondansetron was more pronounced than its anti-nausea effect
(Tramèr et al. 1997). As the anti-nausea effect was weaker with the 4 mg dose, the 8 mg
dose was regarded as the optimal dose. For the treatment of established PONV, a 1 mg
dose of ondansetron appeared to be as effective as higher doses (Tramèr et al. 1997).
When cost-effectiveness is considered, the treatment of established PONV is more effec-
tive than its prevention (Tramèr et al. 1999), but if the prevention is directed at the patients
at high risk for PONV, it is more effective than placebo (Hill et al. 2000). In the extensive Hill
study, 1.25 mg of droperidol was more cost-effective than 0.625 mg of droperidol or 4 mg
of ondansetron. All in all, the regimen of PONV prophylaxis for patients at high risk for
PONV appears to be more cost-effective than treating established PONV (White and Watcha
1999). Compared with dosing before the induction of anaesthesia, dosing near the end of
surgery resulted in better control of PONV (Sun et al. 1997; Tang et al. 1998). In several
studies, ondansetron appears to be more effective in controlling postoperative vomiting
than nausea (Tramèr and Walder 1999). The most hazardous adverse events of the agent
appear to be allergic reactions (Rose and Watcha 1999). Other side effects associated with
ondansetron have been headache, transient increase in liver enzymes, profound hypoten-
sion, dizziness, flushing at IV site, and constipation (Russell and Kenny 1992; Tramèr et al.
1997). Cardiac arrhythmias (Baguley et al. 1997; Kantor 2002) and acute myocardial is-
chemia (Bosek et al. 2000) have been reported in association with the use of ondansetron.
According to recent findings, ondansetron seems to inhibit the analgesic effect of con-
comitantly administered tramadol (De Witte et al. 2001; Arcioni et al. 2002). The mecha-
nism of the phenomenon is suggested to be a counteraction at 5-HT3 receptors which are
responsible for the pain transmission at the spinal level, and tramadol acts by inhibiting
the reuptake and enhancing the release of norepinephrine and 5-HT (Arcioni et al. 2002).
Granisetron
Granisetron has a longer half-life than ondansetron, 3 to 6 hours in healthy volunteers.
(Plosker and Goa 1991). Granisetron, as well as tropisetron, differ from ondansetron in
binding in 5-HT3 receptors. The receptor blockade induced by granisetron or tropisetron
can not be reversed even at high serotonin concentrations, while the effect of ondansetron
can (Newberry et al. 1993). It is unclear whether this difference is clinically relevant. The 40
µg/kg IV dose of granisetron was shown to be the minimum effective dose (Fujii et al.
1998). However, in another study 1 mg of granisetron appeared to be the minimum effec-
tive dose in adults given immediately before the induction of anaesthesia (Wilson et al.
1996). A considerable proportion of the trials published with granisetron have been con-
ducted in one centre, which makes it difficult to evaluate the efficacy of the agent in
antiemetic prophylaxis (Kranke et al. 2001). The high cost of a single dose of granisetron
makes it unsuitable for clinical practice, at least in the USA (Cieslak et al. 1996).
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Dolasetron
After IV administration dolasetron is rapidly converted by the plasma enzyme carbonyl
reductase to hydrodolasetron, which is an active metabolite and appears to be responsible
for the antiemetic effect (Rose and Watcha 1999). Dolasetron has an ultra-short elimina-
tion half-life of 9 minutes, while that of hydrodolasetron ranges from 4 to 8 hours after IV
administration, and 5 to 10 hours after oral administration (Balfour and Goa 1997). The
P450 2D6 isoenzyme is involved in the metabolism of hydrodolasetron (Balfour and Goa
1997). The bioavailability of an oral dose ranges from 70% to 89% (Balfour and Goa
1997). Given at the start of surgery, the minimum effective dose of dolasetron is 50 mg,
but 12.5 mg when given at the end of surgery (Diemunsch et al. 1997; Korttila et al.
1997). In another study, the timing of the 12.5 mg prophylactic dose of dolasetron has no
influence on its efficacy (Chen et al. 2001). Dosed orally 1 to 2 hours before surgery, the
minimum effective dose of dolasetron is 50 mg (Diemunsch et al. 1998). For the treatment
of established PONV, a 12.5 mg dose of dolasetron was the minimum effective dose (Kovac
et al. 1997). The treatment of established PONV with a single dose of dolasetron has been
considered to lead to a reduced need for health care resources (Kovac et al. 1999). The
side effect profile of dolasetron is similar to that of ondansetron: headache, dizziness,
light-headed feeling. ECG analysis occasionally reveals transient prolongation in PR, QRS
intervals and in QTc (Balfour and Goa 1997). These changes are visible at the 12.5, 25, 50
and 100 mg doses, but at the 12.5 mg dose the changes in PR and QTc are comparable
with the placebo group (Kovac et al. 1997; Kantor 2002). The effective dose of dolasetron
seems to be cheaper than the effective dose of ondansetron, at least in the USA (Rose and
Watcha 1999).
Tropisetron
Tropisetron is metabolised in the liver by the cytochrome P450 2D6 system. There are inter-
individual differences in the metabolising speed of the compound because of the polymor-
phism of the enzyme system (Lee et al. 1993). The distribution ratio of the extensive and
poor metabolizers in Caucasian populations is 12:1, respectively (de Bruijn 1992). The
mean elimination half-life ranges from 8 h in extensive metabolizers to between 30 and 42
hours in poor metabolizers (Lee et al. 1993). The bioavailability of tropisetron is dose-
dependent,  ranging from 52–66% (Lee et al. 1993). In a dose-finding study, a 2 mg dose
of tropisetron given before anaesthesia was the minimum effective dose for the preven-
tion of PONV (Capouet et al. 1996). However, most of the studies on tropisetron have
employed the 5 mg dose, which was shown effective for the prophylaxis of PONV after
breast (Chan et al. 1998) and gynaecological surgery (Zomers et al. 1993; Alon et al.
1996). For the treatment of established PONV, the 2 mg dose was the optimal effective
dose (Alon et al. 1998). In a placebo-controlled comparison with 1.25 mg of droperidol,
given at the end of surgery, 5 mg of tropisetron prevented vomiting but not nausea, while
droperidol failed to prevent any emetic events (Purhonen et al. 1997). The side effect
profile of tropisetron does not differ from the profile of other 5-HT3 receptor antagonists.
Tropisetron is marketed in only a few countries at a price a little higher than that of
ondansetron.
Glucocorticoids
After corticosteroids were found effective in chemotherapy-induced nausea and vomiting,
they were used in anaesthesia as prophylaxis against PONV. The mechanism of the anti-
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emetic action of corticosteroids is unknown, but prostaglandin antagonism has been pro-
posed to be the mechanism (Rich et al. 1980), and the release of endorphins is another
explanation suggested for the action (Harris 1982). It has also been speculated that the
mechanism of action is related to the anti-inflammatory and membrane-stabilising effect
(Kovac 2000). The glucocorticoids betamethasone and dexamethasone have been studied
for the prophylaxis of PONV. The half-life of betamethasone is 300 min and that of dexam-
ethasone 200 min, but the biological half-life of dexamethasone is 36–72 h (Schimmer
and Parker 1995). Betamethasone 12 mg given before the start of surgery, compared with
placebo, resulted in a significant decrease of PONV and pain in ambulatory foot and
haemorrhoid operations (Aasbø et al. 1998). In the past few years, dexamethasone has
been investigated extensively in different surgical settings. In a dose-ranging study where
10 mg, 5 mg, 2.5 mg and 1.25 mg doses of dexamethasone were compared with placebo,
2.5 mg dexamethasone was the minimum effective dose for prophylaxis after major
gynaecological surgery (Liu et al. 1999). In another study comparing dexamethasone at
the same doses, a 5 mg dose appeared to be optimal for preventing PONV in patients
undergoing thyroidectomy (Wang et al. 2000). When the effect of the timing of 10 mg of
dexamethasone was studied in a placebo-controlled trial, the timing before the induction
of anaesthesia compared well with the timing at the end of anaesthesia in regard to pre-
venting PONV. The authors suggested that the onset time of the antiemetic effect of dex-
amethasone was about two hours (Wang et al. 2000), which makes its use as a rescue
antiemetic unwarranted. In a quantitative systematic review, a single prophylactic dose of
dexamethasone, compared with placebo was antiemetic displaying a more apparent late
efficacy (Henzi et al. 2000). The systematic review evidenced an increased antiemetic ef-
fect if dexamethasone was combined with a 5-HT3 receptor antagonist. Associated benefi-
cial effects have been reported when glucocorticoids have been used for antiemetic pro-
phylaxis: Considerable pain relief has been demonstrated with the preventive use of 12
mg of betamethasone (Aasbø et al. 1998), and decreased time to home readiness with 4
mg of dexamethasone without evidence of prolonged wound healing (Coloma et al. 2001).
In another meta-analysis the authors recommend the routine use of a single dose of dex-
amethasone during paediatric tonsillectomy for the reduction of PONV (Steward et al.
2001). The side effect profile of a single dose of betamethasone and dexamethasone
appears to be comparable to placebo (Aasbø et al. 1998; Henzi et al. 2000). No problems
with wound healing, or disturbances of glucose metabolism have been reported after a
single prophylactic dose (Henzi et al. 2000).
Combinations of antiemetics
The multifactorial origin of nausea and vomiting gives grounds to presume that a combi-
nation of antiemetics antagonising different receptors would provide better control of
PONV (Heffernan and Rowbotham 2000). At present, when antiemetics of different phar-
macological classes are available, it is possible to combine them without producing addi-
tive side effects via CNS (Kovac 2000). Indeed, combinations of drugs of different classes
have proven to be a method for preventing PONV in high-risk patients (Eberhart et al.
2002). Today it is assumed that there is synergism among different antiemetics (Henzi et
al. 2000). Dexamethasone is considered to potentiate the effect of other antiemetics by
sensitising the pharmacological receptors (Sagar 1991) while it decreases levels of 5-hy-
droxytryptamine in neural tissue (Young 1981) and prevents the release of serotonin in the
GI-tract (Fredrikson et al. 1992).
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Double combinations
Double combinations of different antiemetics have been investigated in various surgical
settings, and as a rule a double combination of drugs is more effective than any drug
alone. A combination of droperidol 2.5 mg and ondansetron 4 mg was shown to be more
effective than either of the drugs alone after abdominal surgery (Pueyo et al. 1996).
Ondansetron 4 mg combined with droperidol 1.25 mg increased the incidence of com-
plete response, compared with droperidol 1.25 mg (92% vs. 78%, respectively) in women
undergoing tubal ligation (McKenzie et al. 1996). When ondansetron 4 mg was combined
with cyclizine 50 mg, the combination resulted in a lower incidence of vomiting than
ondansetron 4 mg after ambulatory gynaecological laparoscopic surgery (Ahmed et al.
2000). Dexamethasone 8 mg combined with ondansetron 4 mg in patients undergoing
major gynaecologic operations resulted in better control of PONV than either of the
antiemetics alone (Lopez-Olaondo et al. 1996). The result was confirmed in a study, in
which the incidence of late vomiting was 4% after the combination prophylaxis compared
with 35% after ondansetron prophylaxis (Rajeeva et al. 1999). McKenzie et al. (1997)
compared a combination of ondansetron 4 mg and dexamethasone 20 mg with
ondansetron 4 mg alone, both with propofol anaesthesia, and did not find a significant
difference between the regimens after major gynaecological surgery. Another comparison
failed to show a decrease in the overall incidence of PONV after the combination of dex-
amethasone 8 mg and ondansetron 4 mg compared with both drugs alone, probably
because the study was underpowered, as stated by the authors (Thomas and Jones 2001).
Granisetron 1 mg combined with dexamethasone 5 mg, and granisetron 1 mg alone,
resulted in a lower incidence of PONV than droperidol 1.25 mg in patients undergoing
abdominal, gynaecological, breast or otolaryngological surgery (Janknegt et al. 1999). In
their study the incidence of nausea, however, was significantly lower after the combina-
tion of granisetron and dexamethasone than after granisetron alone. The antiemetic effi-
cacy of the combination of droperidol 0.625 mg and metoclopramide 10 mg was better
compared with ondansetron 4 mg after laparoscopic cholecystectomy (Steinbrook et al.
1996). Ondansetron 4 mg, droperidol 1.25 mg and dexamethasone 8 mg were compared
in three double combinations; ondansetron combined with droperidol or dexamethasone
was found to be more effective than droperidol with dexamethasone among women un-
dergoing major gynaecological surgery (Sanchez-Ledesma et al. 2002).
Multimodal techniques
A multimodal approach seems to result in a promising outcome in the prevention of PONV.
Among patients undergoing ambulatory laparoscopy, multimodal management (total IV
anaesthesia with propofol and remifentanil, without N2O or neuromuscular blockade, with
aggressive IV hydration, with triple prophylactic antiemetics with ondansetron 1 mg,
droperidol 0.625 mg and dexamethasone 10 mg, and with ketorolac 30 mg) resulted in a
2% incidence of PONV compared with a 24% incidence after standard anaesthesia with
prophylaxis of ondansetron 4 mg, and a 41% incidence after standard anaesthesia with-
out any prophylaxis (Scuderi et al. 2000). The incidence of PONV was 24% after a multidrug
approach with ondansetron 4 mg, dexamethasone 4 mg, droperidol 1.25 mg and
metoclopramide 10 mg, compared with 49% after prophylaxis with propofol-infusion
during the operation and the first four hours after the operation, and 70% in the control
group without any prevention among patients undergoing breast and abdominal surgery
(Hammas et al. 2002). Eberhart et al. (2002) used a multimodal antiemetic approach (total
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IV anaesthesia with propofol, 80% supplemental oxygen, dexamethasone 8 mg, haloperi-
dol 10 µg/kg and tropisetron 2 mg) in a group of high-risk patients with a predicted risk of
79–87%, and compared the outcome with a control group with a risk of 53–57%,
anaesthetised in a standard fashion with propofol-desflurane. The incidence of PONV was
7% after the multimodal approach, and 41% after the standard anaesthesia. The patient
satisfaction was significantly higher after the multimodal management than after the stan-
dard anaesthesia when assessed by the patients’ willingness to pay. In a recent study in
which the patients were anaesthetised with desflurane after propofol induction, the addi-
tion of dolasetron 12.5 mg or ondansetron 4 mg to the antiemetic combination of droperidol
0.625 mg and dexamethasone 4 mg, did not improve the outcome (Tang et al. 2003). In
the light of current data, a multimodal approach with propofol anaesthesia and a combi-
nation of antiemetics, i.e. dexamethasone, 5-HT3 receptor antagonist and droperidol, is a
state-of-the-art protocol when anaesthetising patients with a predicted high risk of PONV.
Miscellaneous
Monitoring the depth of anaesthesia
The dosing of sevoflurane by monitoring the depth of anaesthesia using the bispectral index
(BIS®) of the electroencephalogram, compared with not monitoring, was shown to
decrease the incidence of PONV in the phase II recovery room (16% vs. 40%, respectively),
but not in the PACU among outpatients undergoing gynaecological laparoscopy (Nelskylä et
al. 2001). Interestingly, in another study BIS®-monitoring decreased the incidence of post-
operative nausea after desflurane but not after propofol anaesthesia in patients undergoing
gynaecological surgery (Luginbühl et al. 2003). The impact of the titration of anaesthetics
by monitoring the depth of anaesthesia on PONV warrants further investigation.
Supplemental oxygen
Supplemental oxygen at a concentration of 80% administered during colorectal surgery
and 2 h after surgery, compared to a concentration of 30%, was reported to reduce the
incidence of PONV (Greif et al. 1999). The authors hypothesised that PONV would be
increased by the mild intestinal ischemia leading to a release of e.g. serotonin, and the
supplemental oxygen would prevent the ischemia in the intervention group. It should be
pointed out, however, that in this trial the rescue therapy was not standardised, thus the
rescue antiemetic was given at the discretion of the anaesthetist. The risk factors for PONV
were not controlled between the groups either. The same investigators (Goll et al. 2001)
showed that 80% oxygen administered as above was as effective as ondansetron 8 mg
combined with 30% oxygen in the prevention of PONV following gynaecological
laparoscopy. According to these investigators, supplemental oxygen should not be a rou-
tine anaesthetic regimen, and should not be used for premature infants, patients with
chronic obstructive pulmonary disease or patients undergoing laser surgery, but should be
considered in the case of patient at high risk for PONV (Greif and Sessler 2000). The
advantage of the technique is its low cost and the high availability of oxygen. However, a
group in Finland reconstructed the approach of using supplemental oxygen for patients
undergoing gynaecological day-case laparoscopy, and did not find any difference between
80% and 30% oxygen in regard to PONV (Purhonen et al. 2003). The Finnish group re-
peated the study comparing 50% with 30% oxygen among women undergoing breast
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surgery, and did not find any difference between the two regimens (Purhonen et al. 2003).
Further studies are needed to evaluate the role of supplemental oxygen in the prevention
of postoperative emesis.
Clonidine
The α2-adrenergic agonist clonidine at a dose of 4 µg/kg for premedication was shown to
reduce the incidence of PONV, but the oral intake time was longer and recovery score
lower in comparison with clonidine 2 µg/kg, diazepam 0.4 mg/kg, or placebo in children
undergoing strabismus surgery (Mikawa et al. 1995). Oral clonidine premedication 4 µg/
kg was associated with a significant increase in the incidence of complete response (93%
vs. 67%) compared with premedication with diazepam 0.4 mg/kg among children follow-
ing strabismus surgery without any reported adverse effects (Handa and Fujii 2001).
Clonidine 2 µg/kg given immediately before induction anaesthesia to women scheduled
for breast cancer surgery resulted in a significant decrease in the incidence of PONV com-
pared with placebo with a NNT of 3 without any additive sedation or other clinically impor-
tant side effects (Oddby-Muhrbeck et al. 2002). The mechanism of the antiemetic effect of
clonidine is unclear. Oddby-Muhrbeck considered the mechanism to be multifactorial, re-
sulting from the reduction in anaesthetic need and in sympathetic outflow caused by
clonidine, the analgesic effect of clonidine and its intrinsic effect on α2-adrenergic or other
receptor types. Oral clonidine at a dose of 5 µg/kg given before surgery and at 12 and 24
h after the initial dose, compared with placebo, was shown to reduce the cumulative PCA
morphine dose and the incidence of nausea and vomiting after major knee surgery (Park
et al. 1996). As clonidine is an inexpensive drug and has a favourable side effect profile
when dosed cautiously, it is an interesting addition to the antiemetic drug selection. De-
layed recovery and drowsiness, as well as the risk of hypotension and bradycardia, may
prevent its use particularly in outpatient surgery.
Ephedrine
Ephedrine 0.5 mg/kg was first shown to have an antiemetic effect similar to that of droperidol
0.04 mg/kg, both compared with placebo, during the first 90 min after surgery, but not
during the following 24 h (Rothenberg et al. 1991). In a placebo-controlled study, ephe-
drine 0.5 mg/kg given 10 min before the end of surgery was shown to reduce the inci-
dence of PONV from 46% to 18% during the first 3 h after abdominal hysterectomy, but
there was no difference between the groups during hours 3 to 24 (Hagemann et al. 2000).
As there was no difference in blood pressure between the groups, and the patients were
lying still during the first three hours, the preventive effect of ephedrine on motion sick-
ness can not be the mechanism of action; ephedrine thus seems to have a specific anti-
emetic effect on PONV (Hagemann et al. 2000). However, the antiemetic effect of ephe-
drine seems to be of very limited duration, which makes it a less attractive option as an
antiemetic.
P6 Acupressure
Acupressure is a non-pharmacological method, which has been employed for the prophy-
laxis of PONV as well as for pregnancy-related and chemotherapy-induced nausea (Kovac
2000). In a meta-analysis of non-pharmacological techniques, their use was found prom-
ising in the prevention of PONV (Lee and Done 1999). In the trials included in the meta-
analysis, acupressure was compared with placebo and prochlorperazine. In a placebo-
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controlled comparison among children, acupressure was found as effective as droperidol
in controlling early PONV (Wang and Kain 2002). When acustimulation performed with
Reliefband® was compared with ondansetron 4 mg, the acustimulation resulted in a lower
incidence of PONV (White et al. 2002). For the treatment of established PONV, acustimulation
induced by Reliefband® enhanced the antiemetic efficacy of ondansetron (Coloma et al.
2002). Further studies are required to determine the role of P6 acupressure or acustimulation
in the prevention and treatment of PONV.
Future agents
Substance P and NK1 receptors have turned out to be involved in the regulation of emesis.
(Figure 1) With the use of radiolabelled substance P, neurokinin receptors, including NK1
receptors, have been found in the nucleus tractus solitarius and dorsal motor nucleus of
the vagus nerve in rats and ferrets (Maubach and Jones 1997). The mechanism of the
antiemetic action of NK1 receptor antagonists is suggested to result from their ability to
block the entrance of the emetic stimuli to the CNS (McLean et al. 1996; Grunberg 1997).
Two NK1 receptor antagonists (GR205171, CP-122,721) are in process of clinical testing
(Diemunsch et al. 1999; Gesztesi et al. 2000). The antiemetic activity of CP-122,721 ap-
peared to be superior to that of ondansetron (Gesztesi et al. 2000). In the light of prelimi-
nary clinical studies, the NK1 antagonists warrant further investigation as a new class of
antiemetics.
TREATMENT OF ESTABLISHED POSTOPERATIVE NAUSEA AND VOMITING
PONV – prophylaxis or treatment?
During the past few years there has been debate on whether PONV should be prevented
or treated only when the symptoms turn up (Scuderi et al. 1999). The prophylaxis of PONV
has been opposed due to the limited efficacy and adverse effects of the antiemetic pro-
phylaxis, as well as the cost-effectiveness of treating patients with the symptoms. For
those who defend the treatment, the outcome measured with the incidence and frequency
of PONV is what they call the surrogate end point. From their point of view, the true end
points that should be measured are unplanned hospital admissions and patient satisfac-
tion (Fisher 1999). However, both parties seem to accept that patients at high risk of PONV
benefit from the prophylaxis, and the satisfaction among them is higher with the regimen
of prevention (Scuderi et al. 1999; White and Watcha 1999). Using a decision analysis
model which includes costs, prophylaxis was shown to be cost-effective when the inci-
dence of PONV was more than 30% (Watcha and Smith 1994). Altogether, for the above
reasons routine prophylaxis is not warranted for every patient but should be based on the
assessed individual risk for PONV. Prophylaxis is not justified for patients with a lower than
10% risk for PONV. For patients with a 10–30% risk, a single prophylaxis with e.g. droperidol
should be chosen, and for patients with an even higher risk a multimodal prophylaxis with
5-HT3 receptor antagonist and dexamethasone should be used. When prophylaxis is used,
the doses of the antiemetics chosen should be the minimal effective ones in order to avoid
adverse effects. If a regimen of treatment of established PONV only is chosen, the symp-
tom must be treated in an early phase.
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Treatment of established postoperative nausea and vomiting
While immense efforts have been made to investigate the prevention of emetic events,
there are only sparse trials dealing with established PONV. According to a meta-analysis
on the treatment of PONV (Kazemi-Kjellberg et al. 2001) 5-HT3 receptor antagonists
appear to have an effect on vomiting but their effect on nausea is more obscure. The
meta-analysis showed little evidence of the dose-responsiveness of the drugs: dolasetron
12.5–100 mg, granisetron 0.1–3 mg, tropisetron 0.5–5 mg and ondansetron 1–8 mg
seemed to control further emesis equally. There is even less evidence of the antiemetic
effect of the old antiemetics, droperidol and metoclopramide, in the treatment of PONV,
so these should be further investigated.
If the patient has received antiemetic prophylaxis, the drug for the treatment of break-
through PONV should be chosen from a class other than the one used for prevention. The
effect of 5-HT3 receptor antagonists on the treatment of vomiting is confirmed, but the
anti-nausea effect is not so clear (Kazemi-Kjellberg et al. 2001). If ondansetron 4 mg was
given for prophylaxis, repeat dosing of ondansetron for rescue treatment did not improve
the antiemetic effect compared with placebo among outpatients (Kovac et al. 1999). The
antiemetic effect of dexamethasone seems to start only after 2 h after its administration
(Wang et al. 2000); thus the role of dexamethasone in the treatment of PONV is limited to
the most intractable symptom not responding to any other antiemetic agent. Although in
the literature there is not much evidence of the efficacy of droperidol on the treatment of
PONV, yet the agent has been used for this purpose for 30 years. Droperidol appears to
have an effect on PONV caused by opioids, and is the only antiemetic that has efficacy
against nausea and vomiting associated with patient-controlled analgesia (Tramèr and
Walder 1999). Metoclopramide 10 mg was found to have a placebo effect when used for
prophylaxis (Henzi et al. 1999), but larger doses may have a role in treatment. (Figure 3)
Figure 3. Flow chart for the treatment of established postoperative nausea and vomit-
ing when patients received no prophylaxis, droperidol, droperidol with dexametha-
sone and droperidol with dexamethasone and 5-HT3 receptor antagonist for prophy-
laxis.
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In order to prevent further emetic events, the good nursing care of the patient is a key
issue. The patient should have stable hemodynamics and should be properly oxygenated.
A >35% elevation in systolic blood pressure during the induction of anaesthesia was shown
to be associated with an increased incidence of PONV (Pusch et al. 2002). Hypovolaemia
can cause nausea and vomiting, and should be treated aggressively. A multimodal pain
treatment should be employed.
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AIMS OF THE STUDY
The primary aim of the thesis was to find a regimen to prevent PONV. The effects of
different antiemetics, their combinations and dosing regimens were studied among pa-
tients at high risk for PONV undergoing elective surgery under general anaesthesia. The
specific objectives of this thesis were:
1. To compare the prophylactic antiemetic property of two 5-HT3 receptor antago-
nists, ondansetron and tropisetron dosed IV, both combined with droperidol (II),
and orally in comparison with metoclopramide (III).
2. To test the hypothesis that the overall incidence of PONV after sevoflurane anaes-
thesia with ondansetron prophylaxis is lower compared with propofol anaesthesia,
sevoflurane anaesthesia without prophylaxis serving as a control (IV).
3. To compare the antiemetic property of 5-HT3 receptor antagonist tropisetron with
droperidol (I). Further, to test the hypothesis that the incidence of PONV after single
prophylaxis with 5-HT3 receptor antagonist ondansetron, dexamethasone or
droperidol is lower than after no prophylaxis, and that the incidence of PONV after
double combinations of the drugs is smaller than after any of the drugs given as
single prophylaxis. Finally, to test the hypothesis that the incidence of PONV after a
triple combination of the antiemetics is lower than after any of the double combi-
nations of the drugs (V).
4. To test the hypothesis that the interaction between ondansetron, dexamethasone,
and droperidol is additive or synergistic when given in double and triple combina-
tions to prevent PONV (V).
5. To find out whether the increased incidence of postoperative nausea and/or vomit-
ing is associated with decreased patient satisfaction and increased distress (III, V).
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PATIENTS AND METHODS
PATIENTS
The total number of patients in the present study was 567 in Studies I–IV and 5154 in
Study V. In Studies I–IV, 198 of the patients were scheduled for elective surgery in Lapland
Central Hospital, Rovaniemi, Finland, 343 in Oulu University Hospital, Oulu, Finland, and
26 in Kuopio University Hospital, Kuopio, Finland (Study III). In Study V, 384 of the patients
were undergoing elective surgery in Women’s Hospital, Helsinki University Central Hospi-
tal; the rest of the patients were scheduled for surgery in 28 hospitals in Austria (1 hospi-
tal), Germany (20 hospitals), Great Britain (1 hospital), Finland (2 hospitals), Slovakia (1
hospital), Spain (1 hospital), and Turkey (1 hospital).
Study I was based on 120 ASA physical status I–III patients who underwent laparoscopic
cholecystectomy. The 88 ASA I–III patients in Study II were scheduled for gynaecologic
laparoscopy. Study III involved 179 ASA I–III patients undergoing thyroid or parathyroid sur-
gery. Study IV consisted of 180 ASA I–III patients undergoing breast surgery. Study V was
based on 5154 ASA I–III patients scheduled for various types of elective surgery. (Table 3)
All studies were approved by the ethics committees of the hospitals in question (Stud-
ies I–IV Lapland Central Hospital, Rovaniemi, and Oulu University Hospital, Oulu, Study III
Kuopio University Hospital, Kuopio, and Study V Women’s Hospital, Helsinki University
Hospital, Helsinki and University of Würzburg, Würzburg, Germany). All patients gave
their oral and written informed consent before participation and randomization.
DESIGNS AND PROTOCOLS OF THE ORIGINAL STUDIES
A prospective, controlled and randomized study design was used in Studies I–V. Studies I,
II, III, and V were performed in a double-blind fashion. The patients were randomized
using a table of random numbers, and the codes were contained in a sealed envelope. The
summary of the study design is presented in Table 3.
Study I. Altogether 120 female patients undergoing laparoscopic cholecystectomy were
randomly assigned to receive an IV injection of either tropisetron 5 mg or droperidol 1.25
mg after the induction of anaesthesia. The primary endpoint was the incidence of PONV,
and the second was the use of rescue medication among the study patients during 0–2 h
and 2–24 h of follow-up. The patients were interviewed at 2 h and 24 h after surgery.
Study II. 88 female patients with a history of PONV scheduled for gynaecological
laparoscopy were administered IV droperidol 0.75 mg after the induction of anaesthesia,
and ondansetron 8 mg or tropisetron 5 mg at the end of surgery. The primary endpoint
was the occurrence of PONV and the second was the use of antiemetics. The main out-
comes were monitored for study periods of 0–2 h and 2–24 h and the patients were
interviewed at 2 h and 24 h after surgery.
Study III. 179 female patients who underwent thyroid or parathyroid surgery were
randomly allocated to receive ondansetron 16 mg, tropisetron 5 mg, or metoclopramide
10 mg orally 1 h before anaesthesia, together with premedication. The primary endpoint
was the incidence of PONV and the second was the use of rescue antiemetics during the
follow-up of 0–2 h and 2–24 h. Interviews were conducted at 2 h and 24 h after surgery.
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Study IV. 60 female patients scheduled for breast surgery received an IV anaesthesia
with propofol, while 120 patients were anaesthetized with sevoflurane. 60 patients anaes-
thetized with sevoflurane received an IV injection of ondansetron 8 mg at the end of
surgery. The primary endpoint was the incidence of PONV and the second was the use of
rescue antiemetic medication. The main outcomes were recorded during 0–2 h and 2–24
h follow-up. The patients were interviewed at 2 h and 24 h after surgery.
Study V. 5154 patients with a risk of PONV of 40% or more according to Apfel et al.
(1999) (two or more risk factors), undergoing various types of surgery were stratifically
randomized into the study groups. They received, at an equal ratio, no prophylactic
antiemetics or an IV injection of ondansetron 4 mg, dexamethasone 4 mg, droperidol 1.25
mg, or a double or triple combination of the above drugs. Dexamethasone and droperidol
were administered within the induction of anaesthesia and ondansetron at the end of
surgery. The primary endpoint was the incidence of PONV during the 0–2 h and 2–24 h of
follow-up. The patients were interviewed at 2 h and 24 h after surgery.
METHODS
Premedication and monitoring
All the patients in Studies I–IV were premedicated orally with midazolam 7.5 mg about 1 h
before anaesthesia. In Study V the patients were given premedication with benzodiaz-
epine as customary in the department. The patients in Study III received the study drug
according to their allocation concurrently with premedication. Monitoring included heart
rate (HR), ECG, pulse oximetry (SpO2), end-tidal carbon dioxide (ET-CO2), end-tidal anaes-
thetic concentration, and non-invasive blood pressure. Neuromuscular blockade was moni-
tored using a train-of-four method.
Anaesthesia
In Studies I–IV anaesthesia was induced with propofol 1–3 mg/kg. Before the induction of
anaesthesia in Studies I–IV, the patients were given glycopyrrolate 0.2 mg and fentanyl
2–4 µg/kg. Intubation was facilitated with rocuronium 0.5 mg/kg in Studies I–IV. In Studies
I–IV the patients were subjected to controlled mechanical ventilation via a tracheal tube with
oxygen-enriched air. In Studies I-III the hypnosis was maintained with sevoflurane at an end-
tidal concentration of 1–2.5% (Study I) and 1–2% (Studies II–III). In Study IV, for the mainte-
nance of hypnosis, the patients received either propofol-infusion 3–10 mg/kg/ h or sevoflurane
at an end-tidal concentration of 2%. In Studies I–IV further increments of fentanyl 1-2 µg/kg
were given during the operation as needed, judged on the basis of the haemodynamic
monitoring, i.e. if the blood pressure or pulse rose by 20% from the preceding value. Neuro-
muscular reversal agents were not used in Studies I–IV. In Study I all patients had a nasogastric
tube placed after the induction and removed before the extubation. In Study III, the function
of the vocal cords was examined using a laryngoscope directly after the extubation.
In Study V before the induction of anaesthesia with propofol 2–3 mg/kg the patients
received either a bolus of fentanyl 100–200 µg or an infusion of remifentanil 0.25 mg/kg/
min according to stratification. The intubation was facilitated with rocuronium according
to clinical needs. After the intubation, normocapnic mechanical ventilation was employed
with oxygen in nitrous oxide or oxygen enriched air according to the stratification. Mainte-
nance of hypnosis was achieved with either propofol at a rate of 3–10 mg/kg/h or the
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Table 3. Study designs and patient characteristics in Studies I-V. The primary endpoint of each study was PONV. (PONV=postoperative
nausea and vomiting, IV=intravenously, Q1=25% percentile, Q3=75% percentile). NA=not assessed
I II III IV V
Number of patients 120 88 179 180 5154
Study design Prospective, randomized, Prospective, randomized, Prospective, randomized, Prospective, randomized Prospective,
double-blind double-blind double-blind stratifically
randomized,
double-blind,
placebo-controlled
Study drugs and drug Tropisetron 5 mg, Ondansetron 8 mg, Ondansetron 16 mg, Propofol, sevoflurane, Ondansetron 4 mg,
dosages droperidol 1.25 mg  tropisetron 5 mg, tropisetron 5 mg, ondansetron 8 mg dexamethasone 4 mg,
droperidol 0.75 mg  metoclopramide 10 mg  droperidol 1.25 mg
Dosing regimen of study IV after induction of IV after induction of Orally 1 h before surgery IV at end of surgery IV after induction of
drugs anaesthesia anaesthesia (droperidol), with premedication anaesthesia
at end of surgery (dexamethasone and
(ondansetron and droperidol),
tropisetron) at end of surgery
(ondansetron)
Type of surgery Laparoscopic Gynaecological Thyroid or parathyroid Breast surgery Various types
cholecystectomy laparoscopy surgery of surgery
Gender; females/males 120 / – 88 / – 179 / – 180 / – 4200 / 954
Age (years); mean (±SD) 48 (±15) 39 (±8) 49 (±13) 51 (±13) 47 (±15)
median [Q1, Q3] 49 [36; 61] 40 [33; 45] 49 [39; 57] 50 [43; 59] 46 [36; 58]
BMI (kg/m);mean (±SD) 27 (±4) 25 (±4) 26 (±5) 26 (±5) 26 (±5)
median [Q1, Q3] 26 [24; 29] 24 [22; 27] 26 [23; 29] 26 [22; 29] 25 [22; 28]
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I II III IV V
Number of risk factors for
PONV
0 0 0 0 0 8
1 1 0 0 9 222
2 18 2 20 31 1248
3 51 27 81 75 2112
4 50 59 78 65 1509
Risk for PONV (%)*;
mean (±SD) 65 (±14) 73 (±10) 66 (±13) 61 (±17) 59 (±17)
Duration of anaesthesia
(min); mean (±SD) 114 (±32) 93 (±54) 138 (±70) 111 (±66) 108 (±72)
median [Q1, Q3] 109 [90; 125] 87 [44; 130] 137 [110, 177] 96 [56; 159] 95 [68; 135]
Duration of surgery (min);
mean (±SD) 79 (±30) 64 (±46) 114 (±47) 79 (±61)
median [Q1, Q3] 72 [58; 90] 54 [20; 99] 109 [79; 135] 62 [25; 120] NA
Intraoperative fentanyl
mg/kg; mean (±SD)  4.7 (±1.1) 4.4 (±1.7) 5.7 (±1.8) 4.5 (±1.6)
median [Q1, Q3] 4.8 [3.9; 5.4] 4.0 [3.1; 5.3] 5.6 [4.5; 6.7] 4.3 [3.3; 5.3] NA
*According to a simplified risk score (Apfel et al. 1999).
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volatile anaesthetics (sevoflurane, desflurane, or isoflurane) starting at 1 MAC according
to the stratification. Analgesia during the anaesthesia was ensured with further boluses of
fentanyl 50–100 µg or remifentanil 0.1–0.5 µg/kg/min according to the stratification.
Postoperative symptoms
Postoperative nausea and vomiting
Assessment
In all studies the patients were observed for a period of at least two hours in the PACU,
and for any episodes of PONV for the first 24 h postoperatively. The data were collected in
structured questionnaires. In Studies I–IV a study nurse or one of the investigators inter-
viewed the patients at two hours in the PACU and at 24 h on the ward. The number of
episodes of nausea and vomiting, the request for and the time of rescue antiemetic treat-
ment, and any adverse events were recorded at the time of the interviews. In Studies I–II
the patients were asked to grade nausea as none, mild, moderate, or severe. In Study V
the worst nausea in the PACU was assessed at two hours postoperatively in an interview
by an investigator or the study nurse. At 24 h another interview was conducted or a
written questionnaire including questions on nausea and emetic episodes was filled out by
the patients.
Rescue medication
In Study I the rescue antiemetic treatment was achieved with metoclopramide 10 mg IV. In
Studies II–IV the further antiemetic medication was ensured with droperidol 0.75 mg IV. In
Study V the first emetic event was treated with ondansetron 4 mg IV, the second with
dexamethasone 4 mg IV and the third with droperidol at a dose of 0.5–1.25 mg IV. The
treatment of further emetic events was at the discretion of the investigator.
Postoperative pain
Assessment
In Studies I–IV a study nurse or one of the investigators interviewed the patients at two
hours in the PACU and at 24 h on the ward. The intensity of postoperative pain, opioid
pain medication, and any adverse events were recorded at the time of the interviews.
To assess their average postoperative pain during the study period, the patients used an
11-point numeric rating scale (NRS), 0 standing for no pain at all, and 10 for the worst pain
imaginable. The amount of oxycodone was recorded in milligrams. In Study V, worst pain
was assessed at two hours postoperatively in an interview by an investigator or the study
nurse, and at 24 h by an interview or written questionnaire including questions on pain.
Postoperative pain management
In Studies I–IV the postoperative pain relief was achieved with oxycodone 0.05 mg/kg in
the PACU and 0.1 mg/kg on the ward, and paracetamol 1 g given orally at 8 h intervals. In
Study V the patients received a dose of non-opioid analgesic during the anaesthesia. In
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case the patient was stratified for remifentanil, he or she received a dose of piritramide,
oxycodone, morphine or fentanyl before the end of surgery. In Study V the postoperative
pain medication was provided with non-opioid analgesics given regularly. Further pain
relief was obtained with opioids administered IV, IM, or with the PCA method, or using a
continuous epidural infusion technique with a mixture of local anaesthetics, opioids and
0.9% sodium chloride.
Other postoperative assessments
In Studies I–II, to evaluate the adverse events of droperidol, postoperative sedation was
assessed after the first 2 h in the PACU by nurses on a four-point scale: 1=awake, 2=drowsy,
3=asleep but easily arousable, and 4=fast asleep. The patients assessed their overall drowsi-
ness during the whole study period using an 11-point scale (NRS), where 0 meant alert
and awake, and 10 as drowsy as one could possibly feel.
In Study III the patients were asked to assess their satisfaction with the antiemetic
prophylaxis using an 11-point scale (NRS) (0–10), where 0 meant the lowest possible and
10 the highest possible satisfaction. In Study IV the patients were asked to evaluate their
anaesthesia experience using a scale of worse than expected, as expected, and better than
expected. They were also asked about their willingness to have the same kind of anaesthe-
sia in the future.
In Study V the Myles recovery score (1999) was filled in by the patients at 2 and 24 h
after the anaesthesia. The patients also filled out an anaesthesia satisfaction questionnaire
24 h after anaesthesia. In the questionnaire they were asked to evaluate their distress with
nausea and vomiting separately using a scale of not at all, a little, moderately, and very
much.
Power analyses
The incidence of PONV was the primary endpoint that was used for power analyses in
Studies I–V. Power analyses for Studies I–V were executed with a power of 0.80 and
a significance level of 0.05. The sample sizes were calculated using a formula for categori-
cal data provided by Pocock (1983): n (sample size per group) = [p1 × (100-p1) + p2 × (100-
p2) / (p1-p2)
2] × k, where p1 is the incidence for the control group and p2 the incidence for
the intervention group, and k = constant (7.9, when 1–β = 0.8 and α = 0.05). For Study I
the incidence of nausea after droperidol prophylaxis was assumed to be 50% and after
tropisetron prophylaxis 25%, resulting in a sample size of 55 patients per group. In Study
II the incidence of PONV was assumed to be 50% after tropisetron prophylaxis with
droperidol, and 20% after ondansetron with droperidol. The calculation resulted in a sample
size of 36 patients per group. In the design of Study III, the incidence of nausea was
expected to be 70% after prophylaxis with metoclopramide and 45% after prophylaxis
with 5-HT3 receptor antagonists. The estimation resulted in a sample size of 58 per study
group. In Study IV we estimated the incidence of nausea to be 60% after sevoflurane
anaesthesia and 35% after ondansetron prophylaxis, resulting in a sample size of 59 per
group.
In Study V the incidence of PONV after inhalational anaesthesia was expected to
be 60% and after propofol anaesthesia 40%. With a single antiemetic prophylaxis, the
incidence was assumed to decrease to 26.67%, with a double combination to 17.78%,
and with a triple combination to 11.85%. Based on these assumptions, to find out the
superiority of a triple combination over a specific double combination after propofol
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anaesthesia, 598 patients per group were calculated to be needed for detecting a differ-
ence of 5.92% between the incidence of 17.78% of the double combination and 11.85%
of the triple combination. The three double combinations were grouped and compared
with the triple combination; thus 409 patients were needed per group. Consequently,
23 × 409, i.e. 3272 patients were needed to investigate the effect of the three antiemetics
on patients receiving propofol anaesthesia. As far as volatile anaesthesia was concerned,
it was assumed to lead to a 3/2 higher incidence of PONV than propofol anaesthesia.
We thus needed 249 patients per group to find out the difference between a double
combination and the triple combination, i.e. between 26.67% and 17.78%. This summed
up to 23 × 249=1992 patients and a total of 5264 patients.
Statistical methods
The statistics for all studies were analyzed using the Statistical Package for the Social Sci-
ences (SPSS®) for Windows versions 6.1.3, 7.5, 8.0, 10.0 and 11.0.1 (SPSS Inc., Chicago,
IL, USA). Confidence interval (CI) analyses for Studies I–IV were performed using the CIA
program (Gardner and Altman 1989; Newcombe and Altman 2000). In Studies I–IV the
main outcome was compared by calculating the 95% CI for the differences in proportions
and by calculating a P-value for the null hypothesis of no difference using the X2 or Fisher’s
exact test. To compare the continuous data on the study groups, in Studies I and II we used
the t-test assuming unequal variances, and in Studies III and IV one-way analysis of vari-
ance. For detecting intergroup differences, a post-hoc analysis was performed in Studies III
(Tukey’s adjustment) and IV (least significant difference adjustment). For comparisons of
non-parametric data in Study III the Kruskal-Wallis and Mann-Whitney tests were em-
ployed. In Study V the main outcome was compared between any two interventions by
performing a X2 test and calculating a corresponding risk ratio with a 95% CI. A multivari-
ate analysis was performed by using a binary logistic regression analysis to investigate
further the primary outcome.
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RESULTS
PATIENTS
In Studies I and IV there were no exclusions. In Study II two of the consented 90 patients
were excluded for protocol violations. In Study III six of the consented 200 patients were
excluded because of a re-operation during the study period and 15 for protocol violations.
In Study V 5262 patients had consented to participate, of whom 63 were withdrawn
before allocation into the study groups. Of the randomized 5199 patients, 45 were with-
drawn due to incomplete outcome. Thus 5154 patients were left in the analysis.
OVERALL INCIDENCE OF POSTOPERATIVE NAUSEA AND VOMITING
The overall incidence of PONV after laparoscopic cholecystectomy was 70/120 (58%, 95%
CI 50%–67%), after gynaecological laparoscopy 37/88 (42%, 95% CI 32%–52%), after
thyroid or parathyroid surgery 120/179 (67%, 95% CI 60%–74%), after breast surgery
79/180 (44%, 95% CI 49%–63%) and after various types of surgery in the multicentre
study 1724/5154 (33%, 95% CI 32%–35%) (Table 4, Figure 4).
Table 4. The overall incidences of nausea and vomiting (n (%)) in Studies I–V 0–2 h,
2–24 h and 0–24 h after surgery.
Study I II III IV V Total
Type Laparo- Gynaeco- Thyroid or Breast Various
of surgery scopic logical parathyroid surgery types of
cholecys- laparo-  surgery surgery
tectomy scopy
Number of
patients 120 88 179 180 5154 5721
0–2 h
PONV-free 96 (80%) 77 (88%) 128 (72%) 151 (84%) 4333 (84%) 4785 (84%)
PONV 24 (20%) 11 (12%) 51 (28%) 29 (16%) 821 (16%)  936 (16%)
2–24 h
PONV-free 55 (46%) 57 (65%) 65 (36%) 111 (62%) 3719 (72%) 4007 (70%)
PONV 65 (54%) 31 (35%) 114 (64%) 69 (38%) 1435 (28%) 1714 (30%)
0–24 h
PONV-free 50 (42%) 51 (58%) 59 (33%) 101 (56%) 3430 (67%) 3691 (65%)
PONV 70 (58%) 37 (42%) 120 (67%) 79 (44%) 1724 (33%) 2030 (35%)
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TROPISETRON COMPARED WITH ONDANSETRON, DROPERIDOL,
AND METOCLOPRAMIDE (AIMS 1 and 3)
Incidence of postoperative nausea and vomiting
After laparoscopic cholecystectomy, tropisetron 5 mg and droperidol 1.25 mg, both given
IV, resulted in the same incidence of PONV in the PACU (18% vs. 22%, respectively, ns).
During the entire study period, the overall incidence of nausea was also the same after
both prophylaxis regimens (55% vs. 62%, respectively, ns.), but the incidence of vomiting
was significantly lower after tropisetron (20% vs. 52%, respectively, P=0.01).
When combined with droperidol 0.75 mg IV, the prophylaxis with ondansetron 8 mg
IV or tropisetron 5 mg IV resulted in the same incidence of PONV in the PACU (9% vs.
16%, respectively, ns.) and during the entire study period (36% vs. 49%, respectively, ns.)
among patients undergoing gynaecological laparoscopy.
Tropisetron 5 mg (T), dosed orally 1 h before thyroid or parathyroid surgery, resulted in
a lower incidence of PONV in the PACU compared with ondansetron 16 mg (O) and
metoclopramide 10 mg (M) (15% vs. 32% vs. 39%, respectively, P=0.051 (O-T), P=0.004
(M-T)). During the whole study period, the incidence of vomiting was significantly lower
after the prophylaxis with tropisetron or ondansetron compared with metoclopramide (22%
vs. 34% vs. 53%, respectively, P=0.001 (M-T), P=0.063 (M-O)). The incidence of nausea
was equal after each prophylaxis. (Figure 5)
Figure 4. The total incidences (%) and 95% confidence intervals (CI) of vomiting and
PONV in Studies I–V.
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Consumption of antiemetics
After laparoscopic cholecystectomy the use of antiemetics was the same in the PACU and
during the entire study period after administration of tropisetron 5 mg and droperidol
1.25 mg. (Figure 6)
Figure 5. The incidence and 95% confidence intervals (CI) of vomiting and PONV in
Studies I–IV, 0–2 h, 2–24 h and 0–24 h after surgery.
Figure 6. The proportions (%) and 95% confidence intervals (CI) of patients needing
rescue antiemetic medication in Studies I–IV, 0–2 h, 2–24 h and 0–24 h after surgery.
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Among patients undergoing gynaecological laparoscopy, tropisetron 5 mg and
ondansetron 8 mg, both combined with droperidol 0.75 mg, resulted in an equal use of
antiemetics in the PACU and during the whole study period. (Figure 6)
Among patients undergoing thyroid and parathyroid surgery, the use of antiemetics
was significantly lower after oral premedication with tropisetron 5 mg, compared with
ondansetron 16 mg and metoclopramide 10 mg in the PACU (13% vs. 30% vs. 36%,
respectively, P= 0.045 (O-T), P= 0.006 (M-T)). During the entire study period the use of
rescue antiemetics was lower after tropisetron than after metoclopramide (50% vs. 71%,
respectively, P=0.024) but did not differ after ondansetron prophylaxis (64%). (Figure 6)
Time to the first antiemetic dose
The mean time (95% CI) from the end of surgery to the first antiemetic dose was equal
after prophylaxis with tropisetron 5 mg and droperidol 1.25 mg among patients undergo-
ing laparoscopic cholecystectomy (4 h 46 min (3 h 24 min–6 h 7 min) vs. 5 h 16 min (3 h
38 min–6 h 57 min), respectively, ns.).
After gynaecological laparoscopy, the mean time (95% CI) to the first rescue anti-
emetic dose was significantly longer after ondansetron 8 mg than after tropisetron 5 mg,
both combined with droperidol 0.75 mg (6 h 25 min (4 h 25 min–5 h 4 min) vs. 3 h 18 min
(1 h 57 min–4 h 16 min), respectively, P=0.007).
The mean time (95% CI) to the first rescue medication did not differ after the oral
prophylaxis with tropisetron 5 mg, ondansetron 16 mg and metoclopramide 10 mg among
patients undergoing thyroid or parathyroid surgery (5 h 47 min (4 h 8 min–7 h 26 min), 5
h 14 min (3 h 38 min–6 h 51 min], 4 h 13 min, respectively (2 h 52 min; 5 h 33 min), ns).
(Figure 7)
Figure 7. The mean times and 95% confidence intervals (CI) to the first antiemetic dose
in Studies I–IV.
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Pain and pain medication
In Studies I–III there were no differences among the groups in regard to average pain score
during the whole study period, or the doses of oxycodone in the PACU, or during the
entire study period. (Table 5)
Table 5. Average pain scores (median [Q1, Q3]) and postoperative oxycodone consump-
tion (mg/kg) (mean (±SD)) 0–2 h and 0–24 h after surgery in Studies I–IV. (Q1=25%
percentile, Q3=75% percentile)
Average pain score  Oxycodone
0–2 h 0–24 h
Laparoscopic Tropisetron 5 mg 5 [3, 6] 0.15 (±0.10) 0.38 (±0.20)
cholecystectomy
Study I Droperidol 1.25 mg 5 [4, 6] 0.14 (±0.08) 0.39 (±0.24)
Gynaecological Tropisetron 5 mg + 3 [2, 4] 0.15 (±0.10) 0.29 (±0.25)
laparoscopy droperidol 0.75 mg
Study II Ondansetron 8 mg +
droperidol 0.75 mg 4 [2, 5] 0.19 (±0.12) 0.36 (±28)
Thyroid or Oral tropisetron 5 mg 5 [3, 5] 0.14 (±0.08) 0.35 (±0.22)
parathyroid Oral ondansetron 16 mg 5 [3, 5] 0.13 (±0.07) 0.33 (±0.18)
surgery Oral metoclopramide 10 mg 5 [3, 6] 0.13 (±0.07) 0.34 (±0.22)
Study III
Breast surgery Propofol 3 [1, 4] 0.10 (±0.07) 0.16 (±0.14)
Study IV Sevoflurane 3 [2, 4]* 0.11 (±0.11) 0.16 (±0.17)
Sevoflurane with 2 [1, 3]* 0.09 (±0.08) 0.22 (±0.22)
ondansetron 8 mg
*P = 0.016.
Adverse events
The median of average sedation scores during the entire study period was significantly
higher after prophylaxis with droperidol 1.25 mg compared with tropisetron 5 mg among
the patients undergoing laparoscopic cholecystectomy. The median sedation scores did
not differ among the groups in Studies II and III. (Table 6)
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Table 6. Sedation scores (median [Q1, Q3]) and the incidences of adverse events (%) in
Studies I-IV. (Q1=25% percentile, Q3=75% percentile, NA=not assessed).
Sedation Headache Dizziness Pruritus Tremor, Visual
score restless- disturb-
ness ances
Laparoscopic Tropisetron 5 mg 6 [4; 8]* 37 28 13 7 NA
cholecystectomy
Study I Droperidol 1.25 mg 7 [5; 8]* 27 32 15 15 NA
Gynaecological Tropisetron 5 mg + 6 [4; 8] 14† 23 12 12 NA
laparoscopy droperidol 0.75 mg
Study II Ondansetron 8 mg + 5 [4; 7] 42† 22 11 13 NA
droperidol 0.75 mg
Thyroid or Oral tropisetron 5 mg 6 [4; 7.25] 63 28 13 NA 7
parathyroid Oral ondansetron 16 mg 7 [4.25; 8] 63 45 18 NA 13
surgery Oral metoclopramide 10 mg 7 [5; 8] 54 36 10 NA 12
Study III
Breast Propofol 4 [3; 6] 37 17 7 NA 5
surgery Sevoflurane 4 [3; 7] 30 22 13 NA 5
Study IV Sevoflurane with 4.5 [3; 6] 47 23 10 NA 2
ondansetron 8 mg
*P = 0.023, †P = 0.004.
In Studies I and III there were no differences in regard to the incidences of adverse events
between the groups. Headache was significantly more common among patients receiving
ondansetron 8 mg combined with droperidol 0.75 mg compared with tropisetron 5 mg
combined with droperidol 0.75 mg after gynaecological laparoscopy in Study II. The inci-
dences of other adverse events did not differ among the groups in Study II. (Table 6)
PROPOFOL COMPARED WITH SEVOFLURANE WITH AND WITHOUT
ONDANSETRON PROPHYLAXIS (AIM 2)
Incidence of postoperative nausea and vomiting
After breast surgery, sevoflurane anaesthesia (S) resulted in a higher incidence of nausea
only in the PACU compared with propofol anaesthesia (P), or sevoflurane anaesthesia with
ondansetron 8 mg for prophylaxis (SO) (32% vs. 8% vs. 7%, respectively, P=0.002 (S-P),
P=0.001 (S-SO)). The incidence of vomiting in the PACU was equally low in all groups. The
entire study period considered, the incidence of PONV was lower after sevoflurane anaes-
thesia with ondansetron compared with propofol or sevoflurane alone (27% vs. 45% vs.
60%, respectively, P=0.056 (SO-P), P<0.001 (SO-S)). (Figure 5)
Consumption of antiemetics
In the PACU, the use of rescue antiemetics was higher after sevoflurane anaesthesia than
after propofol anaesthesia, or sevoflurane with ondansetron 8 mg for prophylaxis. During
the entire study period the use of rescue medication was higher after sevoflurane and
propofol anaesthesia than after sevoflurane combined with ondansetron 8 mg (48% vs.
35% vs. 8%, respectively, P<0.001 (SO-S), P=0.001 (SO-P)). (Figure 6)
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Time to the first antiemetic dose
The mean times (95% CI) to the first antiemetic dose were equal after propofol and
sevoflurane anaesthesia with or without ondansetron 8 mg (7 h 26 min (5 h 3 min–9 h 48
min) vs. 7 h 40 min (6 h 2 min; 11 h 17 min) vs. 6 h 15 min (4 h 31; 8 h 19 min),
respectively, ns). (Figure 7)
Pain and pain medication
The median of the average pain scores was higher after sevoflurane anaesthesia compared
with sevoflurane combined with ondansetron. The pain scores did not differ after propofol
anaesthesia compared with either of the sevoflurane anaesthesias. The amounts of
oxycodone given per weight in the PACU and during the entire study period did not differ
between the different types of anaesthesias. (Table 5)
Adverse events
The median sedation scores were equal after all types of anaesthesia. The incidences of
adverse events did not differ after propofol or sevoflurane anaesthesia with or without
ondansetron. (Table 6)
ONDANSETRON, DEXAMETHASONE AND DROPERIDOL COMPARED TO NO
PROPHYLAXIS IN SINGLE, DOUBLE AND TRIPLE COMBINATIONS (AIMS 3 AND 4)
Incidence of postoperative nausea and vomiting
During the first two hours after surgery, droperidol was the most effective of the three
study drugs in the prevention of both nausea and vomiting (Table 7). Both ondansetron
and dexamethasone prevented nausea better than vomiting, but the effect of ondansetron
was stronger. During the initial period of recovery the combination of ondansetron and
droperidol had the strongest efficacy on both nausea and vomiting compared with the
other double combinations, and was equal to the efficacy of the triple combination.
During the later phase of recovery (2–24 h) dexamethasone had the strongest effect
on nausea, and on nausea and retching or vomiting, but the effect on vomiting was equal
to that of ondansetron. The anti-nausea and anti-vomiting effect of ondansetron was
more evident than that of droperidol. Of the double combinations, the combination of
dexamethasone with droperidol was associated with the strongest reduction in retching or
vomiting, and in nausea and retching or vomiting. The other two double combinations of
the drugs were equally effective in the prevention of PONV. The triple combination was as
effective as the combination of dexamethasone with droperidol in decreasing retching or
vomiting. The triple combination reduced nausea and nausea and retching or vomiting
slightly better than the other two double combinations.
During the entire study period (0–24 h), all the three antiemetics were as effective in
the prevention of both nausea and vomiting. The combination of dexamethasone with
droperidol was slightly stronger than the other two double combinations in reducing retching
or vomiting, but did not differ from them in decreasing nausea. The other two double
combinations were equal in preventing nausea and retching or vomiting. The combination
of dexamethasone and droperidol was almost as strong as the triple combination in reduc-
ing retching or vomiting, otherwise the triple combination was the most effective in the
prevention of nausea and vomiting.
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Table 7. Frequencies and odds ratios of retching or vomiting and PONV after no prophylaxis and after single, double and triple prophylaxis
with ondansetron, dexamethasone and droperidol within 0–2 h, 2–24 h and 0–24 h after surgery in Study V. PONV = postoperative nausea
and vomiting.
Ondansetron
No Ondansetron Dexametha- Droperidol Ondansetron Ondansetron Dexametha- with
antiemetic sone with with sone dexametha-
dexametha- droperidol with sone and
sone droperidol droperidol
n = 5154 646 646 647 632 642 637 656 648
0–2 h Retching or
vomiting Incidence n (%) 53 (8.2) 38 (5.9) 46 (7.1) 18 (2.8) 17 (2.6) 18 (2.8) 19 (2.9) 12 (1.9)
Adjusted Relative odds 1.0 0.70 0.86 0.33 0.30 0.33 0.33 0.21
95% CI (ref) (0.45; 1.08) (0.57; 1.29) (0.19; 0.57) (0.17; 0.53) (0.19; 0.56) (0.20; 0.57) (0.11; 0.40)
P 0.104 0.460 <0.001 <0.001 <0.001 <0.001 <0.001
PONV Incidence n (%) 170 (26.3) 121 (18.7) 134 (20.7) 92 (14.6) 81 (12.6) 63 (9.9) 93 (14.2) 67 (10.3)
Adjusted Relative odds 1.0 0.65 0.73 0.48 0.40 0.31 0.46 0.32
95% CI (ref) (0.50; 0.84) (0.57; 0.95) (0.36; 0.63) (0.30; 0.54) (0.23; 0.42) (0.35; 0.61) (0.24; 0.44)
P 0.001 0.018 <0.001 <0.001 <0.001 <0.001 <0.001
2–24 h Retching or
vomiting Incidence n (%) 129 (20.0) 80 (12.4) 79 (12.2) 90 (14.2) 54 (8.4) 55 (8.6) 47 (7.2) 49 (7.6)
Adjusted Relative odds 1.0 0.57 0.56 0.67 0.37 0.38 0.31 0.33
95% CI (ref) (0.42; 0.77) (0.41; 0.76) (0.50; 0.89) (0.26; 0.52) (0.27; 0.53) (0.22; 0.44) (0.23; 0.47)
P <0.001 <0.001 0.007 <0.001 <0.001 <0.001 <0.001
PONV Incidence n (%) 282 (43.7) 199 (30.8) 187 (28.9) 204 (32.3) 141 (22.0) 154 (24.2) 146 (22.3) 122 (18.8)
Adjusted Relative odds 1.0 0.58 0.53 0.62 0.36 0.41 0.37 0.30
95% CI (ref) (0.46; 0.72) (0.42; 0.66) (0.49; 0.77) (0.29; 0.46) (0.32; 0.52) (0.29; 0.47) (0.23; 0.39)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
0–24 h Retching
or vomiting Incidence n (%) 166 (25.7) 105 (16.3) 111 (17.2) 102 (16.1) 66 (10.3) 67 (10.5) 62 (9.5) 55 (8.5)
Adjusted Relative odds 1.0 0.56 0.60 0.56 0.33 0.34 0.30 0.27
95% CI (ref) (0.43; 0.74) (0.46; 0.78) (0.42; 0.73) (0.24; 0.45) (0.25; 0.46) (0.22; 0.41) (0.19; 0.37)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
PONV Incidence n (%) 332 (51.4) 240 (37.2) 241 (37.2) 237 (37.5) 169 (26.3) 179 (28.1) 182 (27.7) 144 (22.2)
Adjusted Relative odds 1.0 0.56 0.56 0.57 0.34 0.37 0.36 0.27
95% CI (ref) (0.45; 0.70) (0.45; 0.70) (0.45; 0.71) (0.27; 0.43) (0.29; 0.47) (0.29; 0.46) (0.21; 0.34)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
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PATIENT SATISFACTION (AIM 5)
The satisfaction of patients was assessed in Studies III–V. After thyroid surgery in Study III
the patient satisfaction score was significantly (P=0.001) higher after oral tropisetron pro-
phylaxis than after metoclopramide (Table 8). The patient satisfaction score did not differ
after oral ondansetron prophylaxis compared with the other two prophylaxes. Discharge
was postponed because of PONV in one patient (2%) after ondansetron prophylaxis, three
patients (5%) after metoclopramide prophylaxis, compared with 0 patients after tropisetron
prophylaxis.
After breast surgery in Study IV, the anaesthesia experience of the patients was equal
after each type of anaesthesia (Table 8). Also their willingness to have the same kind of
anaesthesia in the future did not differ after each type of anaesthesia.
In Study V the patients not receiving prophylaxis were significantly more distressed
with nausea and vomiting than the patients who had been given any single (P<0.001,
P<0.001, respectively), any double (P<0.001, P<0.001, respectively) and the triple prophy-
laxes (P<0.001, P<0.001, respectively). After any single prophylaxis they were more dis-
tressed with both symptoms than after any double prophylaxis (P<0.001, P<0.001, respec-
tively). There were no differences in patient distress after any double antiemetic prophy-
laxes compared with the triple one.
Table 8. Patient satisfaction with the prevention of PONV and with the anaesthesia
experience and willingness to have the same kind of anaesthesia in future.
(PONV=postoperative nausea and vomiting, NA=not assessed, Q1=25% percentile,
Q2=75% percentile).
Patient Willing to
satisfaction have the
with the Anaesthesia experience same kind of
prevention of anaesthesia
PONV  in future
Score Worse As Better
(0–10) than expected than
expected expected
Ondansetron 16 mg;
median [Q1, Q3] 9 [8, 10] NA NA NA NA
Thyroid and
parathyroid Tropisetron 5 mg;
surgery median [Q1, Q3] 10 [8.25, 10] NA NA NA NA
Study III
Metoclopramide 10 mg;
median [Q1, Q3] 8 [5, 10] NA NA NA NA
Propofol; n (%) NA 2 (3) 24 (40) 34 (57) 53 (88)
Breast
surgery Sevoflurane; n (%) NA 6 (10) 28 (47) 26 (43) 53 (88)
Study IV
Sevoflurane with NA 1 (2) 23 (38) 36 (60) 56 (93)
ondansetron 8 mg; n (%)
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DISCUSSION
METHODOLOGY
All the Studies (I–V) in this thesis have been carried out in at least two hospitals. Studies I,
II and IV were performed in two hospitals and Study III in three hospitals in Finland. Study
V was a true multicentre study with 28 participating hospitals in Europe. The obvious
reason for designing studies to be carried out in several hospitals is the power needed for
the study, i.e. sufficient sample size. When factors complicating recovery from surgery and
anaesthesia are investigated, a relatively large sample is generally needed to achieve ad-
equate power in the study (Apfel et al. 2002).
When the study is run in a multicentre mode, there are several problems that should
be avoided in order to maintain a high standard of research. Hospitals have different rou-
tines and regimens in their anaesthesia practice. The doses of opioids used during the
anaesthesia can vary, as well as the dosage of volatile and IV anaesthetics. The routine use
of neuromuscular relaxation and its reversal may differ among the hospitals. The regimen
of postoperative pain medication, the use of NSAIDs and opioids may also diverge. Such
problems were minimized in Studies I-IV because there were no more than two investiga-
tors in each hospital. The use of neuromuscular relaxants and reversal agents was
standardised, as well as the use and the dosage of volatile and IV anaesthetics. The post-
operative pain medication was also standardised. The doses of fentanyl used during ana-
esthesia and the opioids used postoperatively were controlled among the groups. Further-
more, the distribution of the study groups was controlled in each participating hospital.
Study V was stratifically randomised for volatile anaesthetics or propofol, air or nitrous
oxide, and fentanyl or remifentanil, and partly for light or deep anaesthesia according to
BIS®. The use of anticholinergics, antibiotics, reversal agents and postoperative pain medi-
cation was controlled in the groups. After closing the study, a plausibility check was per-
formed in each centre. Thus, although performed in several centres, all the studies were
conducted in a controlled fashion.
Placebo was not used in Studies I–III. The type of surgery was laparoscopic in Studies I
and II, and thyroid or parathyroid surgery in Study III, both of them associated with a high
incidence of PONV. According to an editorial (Gilbertson 1999) and the Declaration of
Helsinki (52nd WMA General Assembly, Edinburgh, Scotland, 2000) placebo may be used
for comparison only if there is no effective treatment with which the study drug could be
compared. Furthermore, in Studies I–III the patients’ mean individual risk (±SD) for PONV
was high (65% (±14), 73% (±10) and 66% (±13), respectively) calculated according to
Apfel et al. (1999). Hence, including a placebo group in Studies I–III was considered un-
ethical. In Study IV the sevoflurane group served as a control, while the propofol group
and the sevoflurane group with ondansetron prophylaxis were to be compared with each
other. In Study V placebo was included. In Study IV the mean individual risk (±SD) was 61
(±17) and in Study V it was 59 (±17). In Study IV breast surgery was included and in Study
V consisted of various types of surgery. The mean individual risk was thus smaller and the
type of surgery was not so uniformly associated with a high incidence of PONV, so a
control group was justified in studies IV and V.
Nitrous oxide was omitted in Studies I–IV in order to avoid additional exposure to a
well-known pro-emetic agent (Tramèr et al. 1996). Furthermore, the patients in Studies I
and II underwent laparoscopic surgery, where omitting N2O is justified because of its high
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solubility and ability to expand cavities such as bowel (Eger and Saidman 1965). However,
N2O was used in equal proportions of patients in the study groups in Study V. One of the
aims of the large multicentre study was to compare the incidence of PONV after anaesthe-
sia with or without N2O. Although N2O appears to be pro-emetic in high-risk patients,
omitting N2O does not result in the total control of PONV. The required dose of opioids
and other anaesthetic agents may be higher when N2O is not used as an anaesthesia
adjuvant.
In a high-quality PONV study, the sample size should be large enough to provide
adequate power, and the group comparability should be based on proven risk factors
(Apfel et al. 2002). Nausea, vomiting and rescue medication should be recorded and re-
ported separately, and they should be observed for 24 h after surgery (Apfel et al. 2002).
The early (0–2 h) and late (2–24 h) recovery should be reported separately. For measuring
nausea, a visual analogue scale (VAS) (0–10 or 0–100), an 11-point numeric rating scale
(NRS) (0–10), or a verbal rating scale (VRS) (none, mild, moderate, severe) may be chosen
(Boogaerts et al. 2000). Boogaerts et al. (2000) compared the VAS and a verbal descriptive
scale (VDS) for assessing postoperative nausea, and concluded that the VAS is suitable for
recording the patient’s opinion about the intensity of nausea. A modification of VDS was
used in Studies I and II. The NRS has been widely used for assessing the intensity of pain as
it correlates well with the conventional VAS (McQuay and Moore 1998). The NRS was
chosen for assessing the intensity of pain in Studies I, II, III and IV, and the patient satisfac-
tion in Study III in this thesis, as it is easy and quick to use. All the rating scales have certain
limitations, such as the transferral of sensation into another dimension (Boogaerts et al.
2000).
NAUSEA AND VOMITING, SEPARATE ENTITIES
In this thesis Studies I–IV failed to identify the patients with vomiting and without nausea.
The patients suffering from vomiting only tend to remain unidentified, as the proportion
of these patients is so small. In Study I 27 (22.5%) out of 120 patients had only nausea,
while 43 (35.8%) suffered from nausea and vomiting, 50 (41.7%) being free from the
symptoms. In Study II 37 patients out of 88 (42.0%) had only nausea, 12 (13.6%) had
nausea and vomiting, and 39 (44.3%) were without PONV. In Study III 56 out of 179
patients (31.3%) had only nausea, and 64 (35.8%) both nausea and vomiting; 59 (33.0%)
were free from the symptoms. In Study IV 32 out of 180 patients (17.8%) had nausea only,
47 (26.1%) had both nausea and vomiting, and 101 (56.1%) had no symptoms at all. In
Study V 990 out of 5152 patients had only nausea (19.2%), 45 (0.9%) vomited without
nausea, 687 (13.3%) suffered from both nausea and vomiting, and 3430 (66.6%) were
free from the complications. In Study V the incidence of vomiting was constantly less than
50% of the incidence of PONV, which may indicate underreporting the incidence of vom-
iting.
Nausea and vomiting are complications that generally occur together. Nausea is a
subjective feeling and may be defined as a desire to vomit, or a feeling that vomiting is
imminent (Andrews 1992). Nausea often occurs in waves. The intensity and duration of
nausea may vary in the course of recovery. Vomiting is an objective endpoint; it is a com-
plex result of central autonomic reflexes and the motor system, which is followed by a
forceful expulsion of GI contents through the mouth (Andrews 1992). Retching is an ex-
pulsive movement of the stomach muscles without expulsion of GI contents. Retching is
usually considered as vomiting (Tramèr 2001). The two endpoints are considered to be
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two biologically different phenomena which should be reported and analysed separately
(Tramèr 2001).
According to a recent epidemiologic study focusing on the difference in risk factors
for PONV, about half of the patients with nausea suffer also from vomiting (Stadler et al.
2003). The proportion of patients with vomiting and without nausea was 2% in their
survey. Female gender, nonsmoking status, and general anaesthesia seem to be risk fac-
tors for both nausea and vomiting, while history of migraine and the type of surgery,
urological surgery excluded, have an impact on nausea only (Stadler et al. 2003). Conse-
quently, nausea and vomiting may have a different physiopathology. Interestingly,
antiemetics prevent nausea and vomiting with a different profile of efficacy, e.g. droperidol
prevents nausea better than vomiting, while 5-HT3 receptor antagonists prevent vomiting
better than nausea (Tramèr 2001). Although there is no standard objective measure for
nausea, it is not a less significant complication compared with vomiting. Intractable nau-
sea lasting for hours may cause more suffering for an individual than a single vomit with-
out any preceding nausea.
POSSIBLE IMPACT OF THE OPERATION SITE ON POSTOPERATIVE NAUSEA AND
VOMITING
In the present study, the overall incidence of PONV was 67% after thyroid or parathyroid
surgery (Study III) and 58% after laparoscopic cholecystectomy (Study I), while the inci-
dence was 42% after gynaecologic laparoscopy (Study II), and 44% after breast surgery
(Study IV). The incidences of PONV in the different studies should not be compared with
each other, e.g. because of the different antiemetic prophylaxis used in each. However, the
anaesthesia regimen used in Studies I–III is quite similar: propofol induction, pain medica-
tion with fentanyl, maintenance with sevoflurane and air, and omitting of neostigmine.
Furthermore, 2/3 of the patients in Study IV were anaesthetized using the above regimen
and 1/3 of the patients received propofol maintenance.
The models for the assessment of the individual risk for PONV differ among other
things in proportion to the role of the type of surgery. The model of Sinclair et al. (1999)
included the type of surgery. In a recent study (Stadler et al. 2003) investigating the differ-
ence in risk factors for nausea and vomiting, the type of surgery, except for urological
procedures, appeared to influence postoperative nausea, but not vomiting. On the other
hand, in the models of Palazzo and Evans (1993), Koivuranta et al. (1997) and Apfel et al.
(1998; 1999) the site of operation did not play a major role. However, the models showing
no relation between the incidence of PONV and the type of surgery can be criticised for
not including an even proportion of patients scheduled for the different types of opera-
tions.
POSSIBLE ASSOCIATION OF PAIN WITH POSTOPERATIVE NAUSEA AND VOMITING
In Studies I, II and III there were no differences in the average pain scores between the
study groups. In Study IV the median of the average pain score was significantly higher
after sevoflurane anaesthesia than after sevoflurane with ondansetron prophylaxis. How-
ever, the postoperative oxycodone consumption was similar in both study groups. As the
difference in the medians of average pain scores between the two groups is an occasional
finding, it is probably a result of chance.
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The possible association of pain with PONV remains unresolved. Only few studies have
come up with a correlation between postoperative pain and PONV (Andersen and Krohg
1976; Chia et al. 2002). It is obvious that the association is extremely difficult to prove
conclusively, as it tends to be demonstrated indirectly. Nevertheless, in order to minimise
the incidence of PONV, all the possible non-opioid methods are necessary in the preven-
tion and treatment of postoperative pain. Further studies are needed to illuminate the
possible correlation between postoperative pain and PONV.
5-HT3 RECEPTOR ANTAGONISTS, DROPERIDOL, DEXAMETHASONE AND THEIR
COMBINATIONS FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
5-HT3 receptor antagonists
In Study II ondansetron was compared with tropisetron, both in combination with droperidol,
as the prophylaxis was directed to the patients at high risk for PONV. In Study III ondansetron
was compared with tropisetron, both dosed orally with the premedication. In Study II the
antiemetic effect of ondansetron and tropisetron appeared to be very similar, except that
the mean time to the first emetic event was shorter after tropisetron than after ondansetron.
The finding is contradictory with the elimination half-lives of the agents, and may be a
result of chance, as the sample size was rather small. In Study III tropisetron prevented
PONV more efficaciously than ondansetron in the early phase of recovery, but in the later
course of recovery the efficacy of the agents seemed to be the same. The better initial
efficacy of tropisetron may be explained by the difference in the potency of the doses of
the two agents. Droperidol given for rescue medication (30% vs. 13% after ondansetron
and tropisetron prophylaxis, respectively) within the first two hours after surgery may inter-
fere with the incidence of PONV during the later phase of recovery. The side effect profile
of the two agents was very similar in both studies.
In the literature, there are only few studies comparing 5-HT3 receptor antagonists with
each other. Ondansetron was shown to be antiemetic and to have dose-responsiveness in
two systematic reviews followed by meta-analyses (Tramèr et al. 1997; Figueredo and
Canosa 1998). The anti-vomiting effect of ondansetron is more evident than its anti-nau-
sea effect (Tramèr et al. 1997). Other 5-HT3 receptor antagonists have not been investi-
gated as extensively as ondansetron. Tropisetron was shown to possess an anti-vomiting
effect, but no anti-nausea effect in a placebo-controlled comparison with droperidol
(Purhonen et al. 1997). The results in Study I were much the same: during the entire study
period tropisetron 5 mg prevented vomiting more effectively but not nausea, compared
with droperidol 1.25 mg.
Altogether, according to the results of Studies II and III, the efficacy and side effect
profile of 5-HT3 receptor antagonists appear to be very similar. The choice of the 5-HT3
receptor antagonist used for clinical practice can be made based on economical reasons.
In general, the dose for prophylaxis should be timed at the end of surgery. (Table 7)
The prophylactic dose of ondansetron varied in Studies II–V. In Study II and IV
ondansetron 8 mg IV was investigated, corresponding to ondansetron 16 mg given orally
in Study III, while ondansetron 4 mg was studied in Study V. The 8 mg dose IV and 16 mg
orally were based on the meta-analysis by Tramèr et al. (1997), in which the anti-nausea
effect of ondansetron 4 mg was weaker compared with 8 mg. For the large multicentre
trial (Study V), ondansetron 4 mg was chosen, because in another systematic review
(Figueredo and Canosa 1998) 4 mg was regarded as the optimal dose. The relative efficacy
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of the 4 mg and 8 mg dose of ondansetron does not differ in Studies II-V; the use of the
smaller dose is thus suggested for prophylaxis.
Droperidol
The results of Study I show a similar overall anti-nausea effect after droperidol 1.25 mg
compared with tropisetron 5 mg for prophylaxis. The incidence of vomiting during the
entire study period was higher after droperidol than after tropisetron. In a systematic re-
view, droperidol was shown to have a more evident anti-nausea effect than an anti-vom-
iting effect (Henzi et al. 2000). Moreover, the anti-nausea effect of droperidol was more
profound during the early phase of recovery (0–6 h) than during the later course of recov-
ery. The short-term antiemetic efficacy of droperidol supports the idea of repeating the
low prophylactic dose particularly when opioids are used for postoperative pain medica-
tion (Tramèr and Walder 1999; Tramèr 2001). In the systematic review droperidol appeared
to be the only antiemetic effective in preventing nausea and vomiting caused by opioids
administered with PCA (Tramèr and Walder 1999). (Table 7)
The 1.25 mg dose of droperidol chosen for Study I corresponds to a dose of 20 µg/kg for
a 60–kg patient. According to the systematic review of Henzi et al. (2000), the antiemetic
effect of droperidol has no dose-responsiveness, whereas the side effects of the agent, i.e.
sedation and drowsiness, are dose-dependent. In the light of these results, a lower dose
should have been chosen for Study I, although the side effect profiles of the two groups
did not differ.
Metoclopramide
Metoclopramide 10 mg was chosen for the comparison of oral ondansetron with tropisetron
in Study III. The overall incidence of PONV was 75% after oral metoclopramide prophylaxis
in patients undergoing thyroid or parathyroid surgery. As the mean individual risk for
PONV was 68% (±12) in the metoclopramide group, the antiemetic efficacy appears to be
negligible. This finding is in line with a systematic review in which metoclopramide 10 mg
was shown to have no significant anti-nausea effect, and the NNT for early and late vom-
iting was 9.1 (95% CI 5.5–27) and 10 (6–41), respectively (Henzi et al. 1999). Unfortu-
nately, Study III was started in 1998 when the above-mentioned systematic review was not
available. In that review no clinically relevant adverse effects were associated with the 10
mg dose of metoclopramide. It is possible that higher doses of metoclopramide have a
more distinct antiemetic effect. In the light of the data in the systematic review, the dose
of metoclopramide should have been higher in Study III.
5-HT3 receptor antagonist, dexamethasone and droperidol alone and
in combinations
In Study V, during the early phase of recovery, the prophylaxis with droperidol was associ-
ated with the strongest reduction in PONV compared with ondansetron and dexametha-
sone. During the later course of recovery, the prophylaxis with dexamethasone was associ-
ated with the strongest reduction of PONV. When the entire study period was considered,
the antiemetic prophylaxis with ondansetron, dexamethasone and droperidol was associ-
ated with an equal reduction of PONV. All the double combinations of the antiemetics
were equal in all phases of the recovery in preventing PONV. The triple combination re-
sulted in an overall incidence of 22% in PONV.
61
All the double combinations appear to prevent PONV equally effectively. However,
according to the results of Study V, all the antiemetics studied appear to act as indepen-
dent drugs. Consequently, the studied antiemetics seem to have an additive effect without
synergism. Any of the combinations may thus be used for the prophylaxis. As the onset
time of dexamethasone seems to be around two hours, as suggested by Wang et al.
(2000), it should be given for prophylaxis rather than as rescue medication. The combina-
tion of droperidol with dexamethasone is justified, as droperidol is effective during the
early hours, and dexamethasone in the later course of recovery. On the other hand, the
combination of ondansetron and droperidol is warranted, as ondansetron has a pronounced
anti-vomiting effect, and droperidol has an evident anti-nausea effect. The combination of
ondansetron and dexamethasone is another rational regimen (Henzi et al. 2000). The
triple combination of antiemetics is justified for patients at high individual risk for PONV,
and for patients for whom vomiting is hazardous. (Table 9)
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Table 9. Clinical aspects in selecting antiemetics for the prevention and treatment of PONV. +++= excellent, ++=good, +=moderate, ±=pos-
sible -=not recommended. (PONV=postoperative nausea and vomiting, EPS=extrapyramidal symptoms).
Optimal time
of Effect on Effective for
administration
Agent Prevention Treatment for prevention Special property Side effects
Early Late
Early Late phase of phase of Nausea Vomiting
recovery recovery
Effective for the
prevention of opioid Sedation, EPS,
Droperidol +++ +++ – +++ +++ ± +++ + induced nausea QTc interval
and vomiting prolongation
More effective for
females than
for males
Headache,
5-HT3 receptor dizziness,
antagonists +++ +++ – +++ ++ ++ + +++ liver enzyme
elevation,
arrhythmias
Adrenal
Pain relief, suppression,
earlier recovery of hyperglycaemia,
Glucocorticoids +++ – +++ – ± +++ ++ ++ anaesthesia, wound healing
stimulating action prolongation,
disturbance of
diurnal rhythm
Metoclopramide – ± – – ± ± ± ± Sedation,
EPS
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ORAL PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
The antiemetic activity of any of the studied drugs in Study III was far from satisfying in the
prevention of PONV after thyroid or parathyroid surgery. Oral prophylaxis for PONV has
not been studied extensively. Indeed, it is an attractive idea to carry out the antiemetic
prophylaxis using a regimen of oral premedication targeted at patients who are at high risk
for PONV. A practice like this would reduce the risk of ignoring the antiemetic prophylaxis.
Considered economically, particularly 5-HT3 receptor antagonists are relatively costly, and
oral drugs are as a rule cheaper compared with IV formulations. The results of the few
studies on oral prophylaxis are nevertheless not very convincing.
The optimal timing of the prophylactic dose of ondansetron has been shown to be
near the end of surgery rather than after the induction of anaesthesia (Sun et al. 1997;
Tang et al. 1998). There are no published studies comparing the timing of the prophylactic
dose for tropisetron. All in all, considering the optimal timing of the 5-HT3 receptor an-
tagonists, oral premedication with them as traditional formulations is not a rational prac-
tice. For ondansetron, an oral disintegrating tablet (ODT) with a freeze-dried formulation
is available. Ondansetron ODT does not require water to be swallowed as it disintegrates
in the mouth. Therefore it could be given to a patient right after anaesthesia or even for
the treatment of established PONV. There are only two published studies comparing
ondansetron ODT 8 mg with placebo. In the first study ondansetron ODT 8 mg was given
prior to discharge from the ambulatory surgery unit, but all the patients had received a 4
mg IV dose at the induction of anaesthesia (Gan et al. 2002). Thus the study is not a true
comparison of ondansetron ODT with placebo. Ondansetron ODT 8 mg given twice a day
for three days, starting on the first evening after operation, did not control PONV better
than placebo among patients undergoing outpatient laparoscopic surgery (Thagaard et al.
2003). Altogether, oral 5-HT3 receptor antagonists do not appear very promising for PONV
prophylaxis.
The optimal timing of the prophylactic dose of dexamethasone was stated to be within
the induction of anaesthesia rather than at the end of surgery (Wang et al. 2000). Consid-
ering the two-hour onset time of the drug activity, the authors suggested, that the oral
dosing of dexamethasone as premedication may be an alternative for IV administration
before the induction of anaesthesia.
For droperidol, only the IV formulation is available. Another butyrophenone, namely
haloperidol, is manufactured in oral preparations. Although shown to possess antiemetic
activity (Kovac 2000), haloperidol has not been investigated nearly as extensively as
droperidol for the prophylaxis and treatment of PONV. If in future, studies on QTc prolon-
gation associated with droperidol lead to the withdrawal of the drug, haloperidol may be
a true alternative for perioperative use as an antiemetic, although QTc prolongation is
associated to some extent with haloperidol as well.
PROPOFOL AND VOLATILE ANAESTHETICS FOR MAINTENANCE
OF ANAESTHESIA
The results of Study IV show a higher incidence of PONV in the PACU after sevoflurane
anaesthesia than after propofol anaesthesia. Moreover, the difference in the incidences of
PONV after sevoflurane and propofol anaesthesia during the later phase of recovery was
not distinct. When ondansetron prophylaxis was combined with sevoflurane anaesthesia,
the incidence of PONV in the PACU was much the same as with propofol anaesthesia, and
smaller compared with propofol or sevoflurane anaesthesia during hours 2–24 after sur-
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gery. Accordingly, in a recent study volatile anaesthetics appeared to be the leading cause
of the PONV occurring in the early phase of recovery (Apfel et al. 2002). In this study the
pro-emetic property of volatile anaesthetics exceeds all the other factors, including the
individual risk factors and antiemetics.
Propofol has been claimed to possess direct antiemetic property (Borgeat et al. 1992;
Gan et al. 1997). When used only for induction of anaesthesia, propofol has no effect on
the incidence of PONV (Tramèr et al. 1997). In this meta-analysis, propofol was shown to
lead to a smaller incidence of PONV compared with volatile anaesthetics, when used not
only for induction but also for the maintenance of anaesthesia. According to the meta-
analysis, the favourable effect of propofol on PONV is short-term (Tramèr et al. 1997).
When the studies with high control incidence for PONV (20–60%) were analysed, the NNT
was 4.7 (early, 0–6 h) and 4.9 (late, 6–48 h). All the studies included in the analysis, NNT
for any emetic event was 6.2 (early) and greater than 9 (late). According to the study of
Apfel et al. (2002) the lower incidence of PONV after propofol anaesthesia in the early
phase is associated with the omitting of volatile anaesthetics rather than with the anti-
emetic property of propofol. Altogether, patients with a high individual risk for PONV and/
or patients undergoing surgery associated with a high incidence of PONV, benefit from
propofol anaesthesia.
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CONCLUSIONS
The following conclusions can be drawn from the studies:
1. Ondansetron and tropisetron are comparable in the prevention of PONV. Com-
bined with droperidol, ondansetron had a longer duration of action than tropisetron.
Dosed orally with the premedication, tropisetron had better efficacy during the
early phase of recovery. The true importance of the differences can be questioned,
as they were inconsistent. Consequently, either of the 5-HT3 receptor antagonists
can be chosen for antiemetic prophylaxis.
2. The incidence of PONV is similar after propofol anaesthesia and after sevoflurane
anaesthesia with ondansetron prophylaxis, while sevoflurane anaesthesia without
antiemetic prophylaxis results in a significantly higher incidence of PONV. When a
patient at a moderate (20–40%) individual risk of PONV is anaesthetized, either
volatile anaesthetic with antiemetic prophylaxis, or propofol, can be chosen for
maintenance. For high risk (≥40%) patients propofol anaesthesia with multimodal
prophylaxis is recommended.
3. The anti-nausea effect of tropisetron is similar to that of with droperidol. The late
anti-vomiting effect of tropisetron is stronger than that of droperidol. The anti-
emetic property during the initial phase of recovery (0–2 h) among the three
antiemetics appears to be, in sequence from the strongest to the weakest, droperidol-
ondansetron-dexamethasone. In the later course of recovery (2–24 h) the antiemetic
effect is of the order, dexamethasone-ondansetron-droperidol. The entire 24-h study
period considered, the antiemetic effect of all three given as single prophylaxis is
comparable, lowering the incidence of PONV by approximately 10–15%. When the
overall outcome is examined, all the double combinations of the drugs are equally
effective, decreasing further the incidence of PONV by 10%. The triple combina-
tion of the antiemetics reduces the incidence of PONV additionally by 5%.
4. Ondansetron, dexamethasone and droperidol, given in double or triple combina-
tions, act with an additive effect without synergism.
5. Increased incidence of either postoperative nausea or vomiting distressed the pa-
tients and was associated with decreased patient satisfaction.
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CLINICAL CONSIDERATIONS
1. For patients at a moderate risk (20–40%) for PONV, a standard anaesthesia regi-
men may be chosen with single or double antiemetic prophylaxis with droperidol,
dexamethasone or 5-HT3 receptor antagonists. For patients at high risk (>40%) for
PONV, propofol anaesthesia is recommended with double or triple antiemetic pro-
phylaxis with droperidol, dexamethasone or 5-HT3 receptor antagonists. (Figure 2)
2. Any of the three antiemetics, i.e. droperidol, dexamethasone, and 5-HT3 receptor
antagonist, may be selected for single prophylaxis. Droperidol may be chosen if
opioids are used to treat postoperative pain. When droperidol is chosen for prophy-
laxis, the repetition of the dose is recommended e.g. after 12 hours. Dexametha-
sone is suitable for prophylaxis, as the onset time of the antiemetic action of the
drug is rather long. (Table 9)
3. Any double antiemetic combination with droperidol, dexamethasone and 5-HT3
receptor antagonist may be chosen for prophylaxis for patients at moderate or high
risk for PONV.
4. The selection of a 5-HT3 receptor antagonist used for prophylaxis can be made
based on economical considerations.
5. The doses of antiemetics used for prophylaxis should be the smallest effective ones
in order to avoid possible side effects, which may be a problem particularly with
droperidol. The recommended dose of droperidol ranges from 0.5–0.75 mg IV and
should be administered at the end of surgery. The optimal dose of dexamethasone
ranges from 2.5–5 mg IV, and the prophylactic dose should be timed at the induc-
tion of anaesthesia. The optimal dose of ondansetron is 4 mg IV, and the dose is
optimally timed at the end of surgery.
6. Multimodal pain medication with NSAIDs, paracetamol and local anaesthetics is
recommended to reduce the need for postoperative opioids.
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